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ABSTRACT

Author: Chen, Chun-Liang. Ph.D.
Institution: Purdue University
Degree Received: December 2016
Title: Functional and Structural Characterization of the Mevalonate Diphosphate
Decarboxylase and the Isopentenyl Diphosphate Isomerase from Enterococcus
Faecalis
Major Professor: Cynthia Stauffacher
Enterococcus faecalis causes a diverse range of nosocomial infections (in wounds,
the gastrointestinal tract, the blood stream and the endocardium), and multidrug-resistant
strains have become a serious issue across countries. Vancomycin, a FDA-approved drug
for the disruption of the bacterial cell wall biosynthesis, has been utilized to treat
infectious diseases caused by Enterococci; however, the prevalence of vancomycinresistant enterococci (VRE) threatens communities all over the world. We aim at
developing novel therapeutic strategies to control bacterial growth of Enterococci, and we
focus on targeting two essential enzymes involved in poly-isoprenoid biosynthesis in
Enterococcus faecalis; one is the mevalonate diphosphate decarboxylase (MDD) in the
mevalonate pathway, and the other one is the isopentenyl diphosphate isomerase (IDI),
which is downstream of MDD. Functional and structural studies on the mevalonate
diphosphate decarboxylase from Enterococcus faecalis (MDDEF) have been conducted
using enzymology, isothermal titration calorimetry (ITC) and X-ray crystallography. We
have used classical enzymology approaches to determine the substrate binding
mechanism of MDDEF, which belongs to a compulsory bi-substrate mechanism with
mevalonate diphosphate (MVAPP) binding first. We also obtained thermodynamic data
on substrate binding in MDDEF using ITC. The results have suggested that enhanced

xvi
binding of the second substrate, ATP, can be achieved by the prerequisite binding of
MVAPP. In structure determination, we obtained several crystal structures of MDDEF
(with or without ligand binding), which represent different states in the enzymatic
reaction. Based on structural comparisons, structural changes upon substrate binding can
be observed. Conformational changes in two non-conserved regions during the substrate
binding event may suggest unique approaches to structure-based specific drug
development in the near future. In the complex structure of MDDEF bound with MVAPP,
ADPBeF3 and Mg2+, the ordering of two regions (97-104 and 183-191) produces a closed
conformation which represents a transitional pre-phosphoryl transfer state. The ligand
architecture implicates a dissociative phosphoryl transfer mechanism during the chemical
steps of the enzymatic reaction. A high-throughput screening method for identification of
inhibitors against MDDEF has been established, and the human MDD protein has been
successfully expressed via auto-induction and purified to homogeneity. Human MDD
will serve as a selection marker for elimination of non-specific compounds targeting the
conserved active-site region in MDD proteins. We have also successfully expressed and
purified the isopentenyl diphosphate isomerase from E. faecalis (IDI-2EF), and have
obtained crystallization conditions and optimized them for crystallizing apo-form IDI-2EF.
Diffraction data were collected at the APS synchrotron source where the apo-form crystal
of IDI-2EF diffracted to a 2.0-Å resolution. We are doing experiments to obtain the bound
form of IDI-2EF. These structures can be further utilized for structure-based drug design
targeting IDI-2EF in the future. In summary, our new findings in MDDEF and IDI-2EF will
provide the detailed enzyme mechanisms and insight into new therapeutic strategies
against multi-drug resistant enterococci.
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CHAPTER 1. INTRODUCTION

1.1

Multi-drug Resistant Enterococci and Nosocomial Infections

After the introduction of penicillin in the 1940s, antimicrobial agents have been
widely used for treatment of infectious diseases to reduce illness and death. However,
these disease-causing microbes have adapted to those antimicrobial agents (Fig. 1.1), and
antimicrobial treatments have become less effective. Multi-drug resistance results from
the abuse of drugs (no need, improper dosing or duration) in humans and food animals 2.
In the United States, a surveillance of antibacterial resistance had been published by
Centers for Disease Control and Prevention (CDC), reporting the deaths and the cost
resulted from infectious diseases and emphasizing the urgency to control drug-resistant
bacteria3. These bacteria have been categorized based on the level of concern: urgent
(Clostridium difficile, carbapenem-resistant Enterobacteriaceae, Neisseria gonorrhoeae),
serious (multidrug-resistant Acinetobacter, drug-resistant Campylobacter, fluconazoleresistant

Candida,

extended

spectrum

Enterobacteriaceae,

vancomycin-resistant

Enterococcus, multidrug-resistant Pseudomonas Aeruginosa, drug-resistant non-typhoidal
Salmonella,

drug-resistant

Salmonella

serotype

typhi,

drug-resistant

Shigella,

methicilline-resistnat Staphylococcus aureus, drug-resistant Streptococcus pneumoniae
and drug-resistant Tuberculosis) and concerning (vancomycin-resistant Staphylococcus
aureus, erythromycin-resistant Group A Streptococcus and clindamycin-resistant Group
B Streptococcus). Among them, we have focused on Enterococcus faecalis V583, a
bacterial strain belonging to vancomycin-resistant enterococci causing a range of
enterococcal infections in clinics, such as bacteremia, urinary tract infections, intra-
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abdominal and pelvic infections, central nerve system infections, skin and skin structure
infections (SSSIs) and infective enterocaditis3-5.
Enterococci are Gram-positive and facultative anaerobes colonized in the
gastrointestinal track. Although they are intrinsically insensitive to detergents and
antibiotics (clindamycin, cephalosporins and aminoglycosides), most of them are
considered commensal bacteria. In the past, clinical enterococcal infections were treated
with vancomycin combined with other antibiotics, such as aminoglycosides. However,
the emergence of drug-resistant enterococci results in difficulties of treatment6-8. The first
clinical isolates of vancomycin resistant enterococci were reported in Europe in 19889,10.
Since then, resistant strains have been widely spread around the world. Vancomycin and
teicoplanin are two kinds of glycopeptides used to treat serious enterococcal infections.
These two drugs form complexes with the D-Ala-D-Ala terminus of the penta-peptide (LAlanine---D-Glutamate---Meso-diaminopimelate---D-Alanine---D-Alanine), prevent the
following transglycosylation and transpeptidation of the peptidoglycan precursors and
thus interrupt the cell wall biosysthesis11. Two types of replacements, D-Ala-D-lactate
and D-Ala-D-Ser, have been reported in literature; bacteria with these two elements in the
construction of the cell wall are considered resistant to vancomycin. D-Ala-D-lactate is
produced by acquired VanA, VanB, VanD and VanM type resistance; D-Ala-D-Ser is
produced by acquired VanE, VanG, VanL and VanN type resistance or intrinsic VanC
type resistance only found in E. gallinarum and E. casseliflavus. Among these, VanA
type resistance is mostly identified from the VRE infections11. VRE are often spread via
direct contact with people with VRE infections or after contact with VRE-contaminated
surfaces. The infections often occur among patients who have been hospitalized for long

3
periods of time, previously treated with vancomycin, had weakened immune systems,
undergone surgical procedures or received medical devices such as urinary or central
intravenous catheters.
Serious infections such as bacteremia and infective endocarditis do require
treatment with antibiotics. For VRE infections, ampicillin monotherapy or combined
ampicillin/aminoglycoside (gentamycin or streptomycin) synergy therapy is commonly
recommended12,13. For the treatment of VRE with ampicillin and aminoglycoside
resistance, linezolid and daptomycin are prescribed. Linezolid and daptomycin are two
drugs approved by the FDA in 2000 and 2003 for the treatment of infections caused by
Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE)14,15. However, it has been shown
enterococci can gain resistance to linezolid16,17 and daptomycin18. Some compounds, such
as Tedizolid, may be viable treatment options in clinical situations with MDR Grampositive pathogens19. However, we could expect that those multidrug resistant organisms
would gain the ability to survive under harsh conditions and selective pressure. For the
improvement of the health care of patients, new approaches against enterococcal
infections are urgently needed. Therefore, we need to develop new antimicrobial active
agents for the treatment of infectious diseases.
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Figure 1.1 The timeline of the introduction of antibiotics and the identification of
drug-resistant gram positive bacteria (staphylococci, streptococci and
enterococci)9,16,20-44. The figure was modified from a published figure in the CDC report,
20133.
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1.2

The Isoprenoid Pathway and the Biosynthesis of IPP and DMAPP in
Enterococci

Thousands of terpenoids, or isoprenoids, identified in nature have been found to be
responsible for diverse cellular functions in archaea, eukaryotes and prokaryotes. Widely
known compounds, such as cholesterol and heme in animals45, bactoprenol and
hopanoids in bacteria, and chlorophylls and carotenoids in plants belong to the
isoprenoids46. The basic elements, isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), are utilized for poly-isoprenoid biosynthesis through a variety of
condensation procedures. These two molecules are known to be produced from either the
mevalonate (MVA) pathway or the methylerythritol 4-phospahte (MEP) pathway47, and ,
and both pathways have been found in different organisms. Some organisms (such as E.
coli) have only the MEP pathway, some have only the MVA pathway (such as human)
and some have both pathways (such as plants) to synthesize IPP and DMAPP. An
enzyme, the isopentenyl diphosphate isomerase (IDI), functions to trigger the
interconversion to adjust the ratio between IPP and DMAPP. For organisms encoding the
MEP pathway, IPP and DMAPP can be produced directly from the MEP pathway, so IDI
is thought to be not essential (as in Bacillus subtilis48). For organisms with the
mevalonate pathway, IPP is the only product synthesized from this pathway and the
DMAPP molecule has to be generated by the IDI enzyme. Thus IDI in such organisms is
considered essential.
In 2000, Wilding et al. reported that the mevalonate pathway is essential in the
gram positive bacteria, enterococci, staphylococci and streptoccci49. This pathway
includes six enzymes, acetyl-CoA acetyltransferase, HMG-CoA synthase, HMG-CoA
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reductase, mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate
decarboxylase (MDD, EC: 4.1.1.33) (Fig. 1.2). The first three enzymes condense three
acetyl-CoA molecules into one molecule of mevalonate, and the two kinases sequentially
add phosphate groups to the 5’ end of mevalonate to produce mevalonate 5’-diphosphate.
MDDs then trigger the last reaction to produce isopentenyl diphosphate (IPP), which is a
fundamental building block for synthesis of isoprenoids in bacteria, and is also involved
in the biosynthesis of bacterial cell wall and electron carriers in the respiratory chain 45,5052

. In Streptococcus pneumonia, with the exception of the acetyl-CoA acetyltransferase,

the rest of the five enzymes in the mevalonate pathway have been identified to be
essential, suggesting MDD in the mevalonate pathway plays important roles in bacterial
growth49. Experiments in mammals have shown that the ATP-dependent decarboxylation
of MVAPP catalyzed by MDD is the rate-limiting step in IPP synthesis53, implicating
MDD may serve as a suitable drug target for the disease treatment. Interestingly, in
Streptococcus pneumonia, an in vitro experiment has indicated that a higher level of
MVAPP can inhibit mevalonate kinase54. This implies the mevalonate pathway is
sophisticatedly regulated by its downstream products. And this strongly suggests that
MDD in the mevalonate pathway can be a promising drug target for treatments of
enterococcal infections.
In the literature, an alternative route of the mevalonate pathway has been found in
some organisms, which have two enzymes, 5-phosphomevalonate decarboxylase and
isopentenyl phosphate kinase, to build up the alternative mevalonate pathway which
bypasses the classical mevalonate pathway. This alternative mevalonate pathway first
catalyzes the decarboxylation of 5-phosphomevalonate, followed by the phosphorylation
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of isopentenyl phosphate46 and the production of IPP (Fig. 1.2). The alternative
mevalonate pathway has now been identified in organisms55. As far as we know, the
genomes of Enterococci encode only the classical mevalonate pathway for IPP
production, which is consistent with the previous findings on the essentiality of MDD in
these organisms.

Figure 1.2 The mevalonate pathway and the alternative mevalonate pathway. All the
molecules are shown in black and enzymes in red. The alternative pathway contains two
enzymes in the route (blue arrows). HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; MVA:
mevalonate; MVAP: mevalonate 5-phosphate; MVAPP: mevalonate 5-diphosphate; IP:
isopentenyl phosphate; IPP: isopentenyl diphosphate; DMAPP: dimethylallyl
diphosphate; AACT: acetoacetyl-CoA thiolase; HMGS: HMG-CoA synthase; HMGR:
HMG-CoA reductase; MVK: mevalonate 5-kinase; PMVK: phosphomevalonate kinase;
MDD: mevalonate diphosphate decarboxylase; PMVD: phosphomevalonate
decarboxylase; IPK: isopentenyl phosphate kinase.
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1.3

Function and Structure of MDD Proteins

MDD proteins trigger irreversible ATP-dependent decarboxylation of MVAPP to
produce IPP in the last step of the mevalonate pathway56 (Fig. 1.3). A conserved aspartic
acid (Asp282 in MDD from E. faecalis) has shown to be a catalytic residue for
deprotonating 3’-OH of MVAPP for the initiation of the reaction57.

Figure 1.3 The reaction of the decarboxylation of MVAPP to IPP by mevalonate
diphosphate decarboxylase (MDD). Mevalonate-5-diphosphate (MVAPP) and
magnesium ATP (MgATP) are the two substrates of MDD enzymes. Magnesium ADP
(MgADP), carbon dioxide (CO2), phosphate and isopentenyl diphosphate (IPP) are
products.

Although functional and structural analysis has been conducted to reveal several
key residues in the active site of MDDs for substrate binding and enzyme catalysis57-59,
there are remaining challenges and questions in this field that hamper the progress on
development of new inhibitors against MDDs and the study of the MDD enzyme
mechanism at the molecular level. Currently there is no suitable model for explaining
conformational changes of MDDs upon substrate binding. In 2012, Barta et al had solved
several crystal structures of MDD from Staphylocuccus epidermidis in complex with
FMVAPP and ATPS, two analogues of MVAPP and ATP59. However, those MDDSE
structures have not provided a comprehensive understanding on how this enzyme
responses to substrate binding (Table 1.1). In their structure models, the -thiophosphate
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of ATPS is far from the 3’-OH group of FMVAPP even though it is in the active site of
MDDSE. The electron density map of this particular structure, MDDSE-FMVAPP-ATPS
was defined poorly in the active site region. In their structures, there is no piece of
evidence for elucidating detailed enzyme catalysis, including the metal binding site(s)
and the detail chemical steps of MVAPP decarboxylation. There is no structural
information about how metal ions are involved in MDD enzymatic reaction although it is
known to be divalent-ion mediated60(Table 1.1). Further, lower values of the real-space R
factor and real-space correlation coefficient of ATPS in the 4DPT and 4DPU structures
indicate a potentially poorly fit for the ligand (Table 1.1). These suggest that there are
questions that need to be resolved before utilizing the structural information for rational
drug design. Before we look into novel structure-based drug development, we will need
to address these unsolved problems. In our research, we study MDD from Enterococcus
faecalis (MDDEF) from functional, biophysical and structural points of view in order to
explain the behavior of MDDs as it triggers the ATP-dependent decarboxylation of
MVAPP.
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Table 1.1 Structural information of the published structures of MDD from S.
epidermidis59*.
PDB accession code

4DPT

4DPU

4DPW

4DU7

Protein

MDDSE*

MDDSE

MDDSE

MDDSE

Wild type/mutation

Wild type

S192A

D283A

Wild type

Ligands

FMVAPP

FMVAPP

MVAPP

MVAPP

ATPS

ATPS

ATPS

--

7

7

7

7

2.2

1.9

2.6

2.2

Rwork/free

18.0/24.0

17.9/22.4

19.1/25.1

19.1/23.9

Undefined region

184-193

--

--

183-186

Metal ion

No

No

No

No

Distance between 3’-O of
MVAPP (or FMVAPP) and -P
of ATPS (Å )**
Estimated coordinate error (Å )#

5.5

5.9

6.1

--

0.29

0.24

0.36

0.28

Real-space R factor /Real-space
correlation coefficient##
Overall

0.131 / 0.940

0.106 / 0.950

--

0.119 / 0.946

FMVAPP

0.222 / 0.942

0.158 / 0.910

--

0.139 /0.978

ATPS

0.225 / 0.833

0.183 / 0.828

--

--

pH of crystallization condition
Resolution (Å )

No
O--NH of
G103, L104
and A105
*MDD stands for the mevalonate diphosphate decarboxylase and SE stands for Staphylococcus
epidermidis. **Distance between atoms is measured in Pymol61 in each case.# Coordinate error of each
structure is obtained in each structure file (.pdb)62. ## Real-space R factor (RSRF) is represented as
Interactions between ATPS
and the phosphate binding loop

∑ |𝜌𝑜𝑏𝑠 − 𝜌𝑐𝑎𝑙𝑐 |
∑ |𝜌𝑜𝑏𝑠 + 𝜌𝑐𝑎𝑙𝑐 |

O--NH of
A105

No

, where obs is the -weighted 2mFo-DFc map and calc is the calculated Fc map, and Real-

space correlation coefficient (RSCC) is calculated between these two density arrays. RSRF and RSCC
values are obtained from the Electron Density Server (EDS) 63.
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1.4

Drug Development against MDDEF

According to the CATH analysis, the overall structure of the MDD family of
proteins contains and  secondary structure elements (  class) and the folding
architecture is characterized to a 2-layer sandwich64. The protein family annotation
(Pfam)65 indicates MDD proteins belong to the GHMP kinase (galactokinase, homoserine
kinase, mevalonate kinase and phosphomevalonate kinase) superfamily, which catalyzes
ATP-dependent reactions. Although mevalonate diphosphate decarboxylases were
identified and studied several decades ago56, there has not been much progress on filling
the gap between protein structures and specific drug design for application in disease
control. The reason why this approach to antibiotic development has not been pursued
might be because the mevalonate pathway exists not only in prokaryotes and archaea, but
also in eukaryotes, including humans66. In the MDD family of proteins, the active site
environment is highly conserved67 (Fig. 1.4), and that could make development of
specific drugs against MDDEF more challenging. Success in developing drugs specifically
targeting one member of a family of proteins with similar active sites will rely on subtle
difference in the actives sites. In the case of virtual high-throughput screening and
inhibitory studies for identifying selective compounds against the dihydrofolate reductase
(DHFR) from Pneumocystis carinii68, a 25-fold selectivity for Pneumocystis carinii
DHFR (IC50 = 7 M) over human DHFR (IC50 = 200 M) suggests the importance of
contacts between compounds and non-identical residues in the active site for compound
selectivity. It is known that 6-FMVAPP, a substrate analogue of MVAPP, can bind to the
MVAPP binding pocket of MDD from Staphylococcus epidermidis (PDB code: 4DPT
and 3QT5)59,67. Kinetic studies on MDD from humans (62 nM)67,69, S. epidermidis (49
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nM)

67

, yeasts (750 nM)70and rats (37 nM)71 also show 6-FMVAPP is a competitive

inhibitor of MVAPP targeting the entire MDD family of proteins with very similar Kis.
Thus, it is important to develop new strategies to achieve specific drug design against
MDD since it is, to our best understanding, a promising drug target in the mevalonate
pathway. We will discuss our experimental results in the following chapters and how they
provide insight into the connection between the structure and function of MDDEF, which
will aid in the development of new antibacterial drugs

Figure 1.4 The overall structure of MDDEF and structure-sequence alignment. The
homology model of MDDEF was generated using the apo crystal structure of MDD from
Staphylococcus epidermidis (3QT5) as a template. Three MDD protein sequences of H.
sapiens, S.epidermidis and E. faecalis were aligned and the sequence conservation within
them was color-coded on the homology model in blue (identical), white (similar) and red
(non-conserved). Active site region is indicated by a green dash-line box and the position
of the catalytic residue (D282) is indicated by a green star.
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CHAPTER 2. CRYSTAL STRUCTURE OF MDDEF CO-CRYSTALIZED WITH
ATP INDICATES THE BINDING OF MVAPP IS CRUCIAL FOR THE
BINDING OF ATP TO ITS CATALYTICALLY-FAVORED POSITION IN
THE ACTIVE SITE OF MDDEF

2.1

Chapter Summary

The findings from the crystal structures of the mevalonate diphosphate
decarboxylase from Staphylococcus epidermidis (MDDSE) implied a sequential ordered
substrate binding mechanism during MDD enzyme catalysis59. The substrate binding
order of the MDD from chicken was first determined in 1987, in which MVAPP was
suggested to be the first substrate72. However, no suitable molecular models were
available for illustrating the substrate binding mechanism and overall conformational
changes of the protein upon substrate binding. In this study, we obtained a co-crystal
structure of MDDEF bound with ATP at a 2.1-Å resolution. In this structure we found that
the initial binding of ATP leaves the -phosphate outside the active site. By comparing
our structure with the complex structure of MDDSE bound with two substrate analogues,
FMVAPP and ATPS (MDDSE-FMVAPP- ATPS)59, we observed differences in the
position of the phosphate binding loop of MDDEF and the phosphate tail of ATP. These
findings lead us to hypothesize the prerequisite binding of MVAPP is important for ATP
binding site
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2.2

Introduction

MDD (EC: 4.1.1.33) acts on MVAPP to produce IPP56, and IPP serves as a
fundamental building block for the synthesis of diverse isoprenoids45,50. From the
enzymatic reaction, we know that MDD proteins have two substrates, MVAPP and ATP
(Fig. 1.3). The observation from previous structural models of MDDSE bound with
different ligands suggested that MVAPP is the first substrate, based on the binding site
located in the deep active site cleft of MDD59. Whereas, some key features regarding
enzyme catalysis were missing in their structures, indicating the structure models might
not be representing the states during the enzymatic reaction (Table 1.1). Three decades
ago, the kinetics of MDD proteins isolated from the chicken liver were investigated. The
enzymology data suggested that MDD proteins a sequential ordered bi-substrate
mechanism with MVAPP as the first substrate60,72. However, there is no comparable
evidence to support that MDD from Enterococcus faecalis will act on substrates in the
same manner. And the question we would ask is that if ATP can also bind MDD proteins
without MVAPP binding to the deeper cleft. There are structures of MDD bound with
different ligands (Table 1.1), but there is not an MDD structure with ATP or ATP
analogues alone. Here we aimed to obtain a crystal structure of MDDEF bound with ATP
to see if there is any difference between MDDEF-ATP structure and those published
(Table 1.1). With that, we could possible know how the two substrates bind to the active
site and why MVAPP has been suggested as the first substrate of MDD proteins.
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2.3

2.3.1

Materials and Methods

Cloning, overexpression and purification of the recombinant form of MDDEF
A gene fragment encoding MDD from Enterococcus faecalis (MDDEF) was

amplified via PCR and sub-cloned into the expression plasmid pET30a73. Upon
confirmation of the DNA sequence, the construct was transformed into Escherichia coli
BL21 (DE3). Transformed cells were cultured in LB broth supplemented with kanamycin
(50 mg/ml) at 37℃ to an A600nm of 1.0. Protein expression of MDDEF was induced by
addition of isopropyl 1-thio--D-galactopyranoside (IPTG) (0.1 mM) for another 4 hours
at 37℃. Cells were harvested by centrifugation at 8000 rpm, re-suspended in binding
buffer (50 mM sodium phosphate at pH 7.4, 300 mM NaCl, and 10 mM imidazole), and
lysed to homogeneity by French Press. His-tagged MDDEF protein was soluble in the
supernatant after centrifugation and trapped on a Ni2+-NTA column followed by the
elution with increasing concentrations of elution buffer (50 mM sodium phosphate at pH
7.4, 300 mM NaCl, and 300 mM imidazole). Eluted collections were pooled and desalted
against dialysis buffer (25 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 10 mM MgSO4)
twice, the first one with -mercaptoethanol (2-ME) (20 mM) and the second one without
2-ME. The N-terminal His-tag was removed from MDDEF by treatment with recombinant
tobacco etch virus (TEV) protease in dialysis buffer containing 1 mM DTT and 0.5 mM
EDTA for overnight at 4 ℃ followed by an final dialysis procedure in the dialysis buffer
without DTT and EDTA. His-tagged TEV and residual His-tagged MDDEF were removed
by passing the protein mixture through nickel affinity resin. The artificial sequence NA
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remains at the N terminus of MDDEF after the TEV treatment. The purified MDDEF
protein solution was concentrated to 8 to 10 mg/ml by ultrafiltration and stored at -20 ℃.

2.3.2

Protein crystallization, data collection and structure refinement
The co-crystal of MDDEF in complex with ATP (MDDEF-ATP) grew under the

crystallization condition (10 mM ATP, 26% PEG 3350, 50 mM sodium acetate, pH 4.6,
and 5 mM MgCl2) by sitting drop vapor diffusion. First, ATP was added to the protein
solution to a final concentration of 10 mM. 1 l of MDDEF-ATP solution was mixed with
1 l of the reservoir. Crystals formed after a two-day equilibrium. Cryo-protectant (26%
PEG 3350, 17% PEG 400, 50 mM sodium acetate, pH 4.6, and 5 mM MgCl2) was
prepared and gradually added into the protein-reserviour mixture to prevent ice formation
when flash-freezing the crystal in liquid nitrogen. The diffraction data of MDDEF in
complex with ATP were collected at the 23-ID-D beamline at the Advanced Photon
Source (APS) in Chicago. The HKL2000 software was used for space group
determination, data integration, data reduction and data scaling74, and after data
processing, the scalepacked reflection file (.sca) would be generated. The software in
CCP4, scalepack2mtz, was then used to convert the scalepack reflection file (.sca) to an
MTZ format (.mtz) with R-free flag assigned (5%)75. We then used the molecularreplacement method in phenix.phase to solve the phases of the structure and refined the
structure in phenix.refine76.
The molecular-replacement (MR) method77,78 has now been widely employed to
estimate the phases of an unknown structure from an analogous structure (homologues)
and the estimated phases were then combined with experimentally derived amplitudes of
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structure factors to solve the unknown crystal structure. The fundamental procedure of
the molecular replacement method composes of the rotation function and the translation
function, which can be expressed as Equation 2.1, where X is the coordinates of atoms in
a homologous macromolecule, [R] is the rotation matrix, T is the translation vector and X’
is the coordinates of atoms in an unknown structure.

𝑋 ′ = [𝑅 ]𝑋 + 𝑇
Equation 2.1

In the MR method, the problem with searching possible solutions in the sixdimensional space (Eulerian angles: ,  and ; Cartesian coordinate: x, y and z) can be
reduced by searching the orientation of the molecule in the step of rotation function,
followed by searching the position of the molecule in the step of translation function. The
original rotation function searches a good agreement between two Patterson functions
corresponding to the unknown and the homologue structures within a certain range (cutoff radius) in the Patterson space, and the original rotation function is shown in Equation
2.2,

R (θ1, θ2, θ3) = ∫ 𝑃1 (𝑥)𝑃2 (𝑥 ′ )𝑑𝑥
𝑈

Equation 2.2

where R() is the rotation function, P1 is the Patterson of a model, which will
rotate by the angles  and then superimposed to P2, the Patterson of the unknown
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structure. Once the orientation of the unknown structure is determined, the translation
function will be utilized to search the position of all the molecules in the unit cell until a
good fit between the predicted structure factors of the model (Fcalc) and the
experimentally measured structure factors of the unknown structure (Fobs) is obtained.
The program Phaser in phenix (phenix.phaser) also applies the molecular replacement
strategy to solve the phase problem and maximum-likelihood methods have been used in
the rotation and translation functions79.
We used phenix.phaser to estimate the phases and determine the structure of
MDD from Enterococcus faecalis. The crystal structure of MDD from Staphylococcus
epidermidis (MDDSE, PDB: 3QT5) was used as a template to generate a modified search
model by CHAINSAW in CCP480 for the following molecular replacement. In
CHAINSAW, a search model can be generated based on the given structure (3QT5) and
the sequence alignment results (MDDEF aligned to MDDSE), and the mode can be
selected to create a poly-alanine model or a model with the maximal number of atoms
common to the target and model residues. The phases of the crystal were determined by
Molecular Replacement in phenix.phaser76 using the poly-alanine structure as a search
model. In each step of molecular replacement, only one solution was found. The rotation
function with log-likelihood gain (LLG) greater than 0, the translation function with Zscore (TFZ) greater than 8 and no violations after the packing analysis also suggest the
success in solving the phases using molecular replacement. No violation after the packing
analysis also confirmed the correct selection of the space group.
After phase determination by molecular replacement, the first structure refinement
was performed in phenix.refine76. During structure refinement, strategies for refining the
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model geometry (XYZ coordinates), atomic positions (Real-space), and atomic B factors
(individual B-factors) were chose, and after the refinement, missing side-chains of the
residues in the structural model were manually rebuilt in the graphical program Coot81
based on the observation of the electron density map (2Fo-Fc) and the difference map
(Fo-Fc). Although using a poly-alanine search model can reduce model bias coming from
the structural model, in the refinement strategies, simulated annealing (Cartesian or
Torsion angles) was also employed in the first few runs of structure refinement to reduce
model bias. In phenix, we also used phenix.autobuild to generate density modified maps
(solvent flattening) and phenix.composit_omit_map to generate the omit map and used
the maps to evaluate the structural model. In the following refinements, more
sophisticated options, such as target functions, can be chose for refining the weight
between X-ray data and the structural model (Optimize X-ray/stereochemistry weight,
Optimize X-ray/ADP weight). Water molecules were also be built by either phenix.refine
or Coot, and inspected in the Coot interface.
The crystallographic information file (.cif) and the PDB format file (.pdb) of ATP
were generated using phenix.eLBOW76. After few runs of structure refinement (without
ligands), ATP was manually placed and fitted into the weight difference electron density
maps (mFo-DFc) in Coot81. Geometry and rotamer outliers were gradually reduced after
several runs of structure refinement and a satisfied structure with ligand(s) was obtained.
Finally, the ATP molecule in that particular structure would be omitted by setting the
ligand occupancy to zero or simply removing it from the structure for calculating a
simulated annealing (SA) ligand omit map using phenix.composite_omit_map, to depict
the electron density of ATP in the ATP binding pocket of MDDEF61.
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2.3.3

Multiple sequence alignment of the MDD family of proteins
The sequences of MDD proteins from organisms (Enterococcus faecalis;

Enterococcus

faecium;

Staphylococcus

epidermidis;

Staphylococcus

aureus;

Streptococcus pyogenes; Listeria monocytogenes; Homo sapiens; Trypanosoma brucei;
Mus. musculus; Xenopus tropicalis; Bos taurus; Arabidopsis thaliana) were aligned using
EBI Clustal Omega82. A pairwise identity score matrix was generated based on the
sequence alignment results.

2.4

2.4.1

Results

Protein expression and purification
His-tagged MDDEF was overexpressed in the E. coli (BL21) expression system

and then purified via nickel-affinity chromatography (Fig. 2.1a). Proteins were eluted
from the column by elution buffer containing 300 mM imidazole. After the elution, each
fraction was examined by SDS-PAGE (Fig. 2.1b) and fractions with about 95%-pure
MDDEF were collected for a following two-step dialysis. The purpose of dialysis is to
eliminate the imidazole concentration which will affect the protein stability after a freezethaw step in our study. In the first step of dialysis, 2-mercaptoethanol (2-ME) was added
into the dialysis buffer to a final concentration of 20 mM to avoid protein aggregation,
and in the second step of dialysis, protein solution was dialyzed against original dialysis
buffer to get rid of 2-ME. After that, we used an overnight TEV-protease treatment to
remove the N-terminal His tag in dialysis buffer containing DTT and EDTA. Before
separating the His-tagged TEV proteases from the His-tag-removed MDDEF by Ni-
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affinity resin, the protein mixture was dialyzed to remove DTT and EDTA. Finally, we
obtained pure TEV-treated MDDEF protein (Fig. 2.1c) with a protein yield of 120 mg per
liter.

22

Figure 2.1 Protein purification of MDDEF. (a) The purification profile of MDDEF. The
detailed procedures of protein purification are discussed in the text. (b) The SDS-PAGE
gel for the MDDEF protein purification. (M: Protein marker; Pellet: the sample in the
pellet after French press; Flow through: an aliquot of flow-through containing proteins
which cannot be trapped on a Ni-NTA column; 5~18: fractions of elution). (c) The SDSPAGE gel for the TEV-protease-treatment profile of MDDEF. 0, 4 and *16hrs: TEV
treatment at different time courses; *: dialysis against buffer without DTT and EDTA;
RT: treatment at room temperature; Flow through: an aliquot containing proteins which
cannot be trapped on a Ni-NTA column; Strip: an aliquot after 1 ml of strip buffer
(containing 50mM EDTA) flowing through the column.
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2.4.2

Protein crystallization, X-ray data collection and structure determination
The first crystal structure of MDDEF co-crystallized with ATP (MDDEF-ATP) was

obtained from a crystal diffracted X-rays to a 2.1-Å resolution and as collected at the
APS synchrotron. We used the HKL2000 software to process the data and the resolution
cut-off for the last shell (highest resolution) was determined based on the data
completeness (>90%) and I/value (>2). The space group of the crystal was P21212 (a, b,
c = 82.0, 97.7, 46.3 Å ; ) determined by the software Pointless in CCP4 and
phenix.phaser76,83. One molecule was expected in an asymmetric unit assistant with the
Mathew coefficient and the water content of that particular crystal (cell volume:
370710.5 Å 3, molecular weight: 36489.5 Da, Mathew coefficient: 2.54; % solvent: 51.6).
A monomeric structure model generated from the crystal structure of MDD from
Staphylocuccus epidermidis (PDB: 3QT5) was used as a search model for solving phases
by Molecular Replacement in phenix.phaser. Structure refinement was done in
phenix.refine and the final Rwork/Rfree was 18.3/21.3. All the statistics of data collection
and refinement are listed in Table 2.1.
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Table 2.1 Data collection and refinement statistics of MDDEF-ATP*
MDDEF-ATP
Data collection**
Space group
Cell dimensions
a, b, c (Å)
()
Resolution (Å)
Rmeas (%)
I /I
Completeness (%)
Redundancy
CC1/2 (%)
CC* (%)
Refinement
Resolution (Å)
No. reflections in test/free R
Rwork / Rfree (%)
Estimated coordinate error (Å)
No. atoms
Protein
Ligand/ion
Water
B-factors
Protein
Ligand/ion
Water
R.m.s. deviations
Bond lengths (Å)
Bond angles ()
Ramachandran Plot
Most Favored (%)
Allowed (%)
Outliers (%)

P21212
82.0, 97.7, 46.3
90.0, 90.0, 90.0
40.0–2.1 (2.18–2.10)
7.5 (40.9)
14.3 (2.3)
99.8 (99.8)
4.4 (4.1)
92.7
98.1
33.6 – 2.1
21102/1140
18.3 / 21.3
0.21
2483
36
160
26.1
51.0
30.8
0.006
0.75
98.42
1.58
0

*Single crystal grown under the condition containing 10 mM ATP, 26%
PEG 3350, 50 mM sodium acetate, pH 4.6, and 5 mM MgCl2.
**Structure determined from one crystal. Values in parentheses are for the
highest-resolution shell.
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In MDDEF-ATP, the overall structure of MDDEF and ATP in the binding pocket
(Fig. 2.2a) were determined, except for a non-conserved loop (184~192), the 10-4 loop,
which is between two secondary structure elements, 10 and 4. The simulatedannealing ligand omit map was generated in phenix.composit_omit_map to demonstrate
the location and architecture of ATP with less model bias, and the mesh representing the
electron density of ATP was contoured at 2.5  (Fig. 2.2b). The adenine base of ATP
forms direct and indirect hydrogen bonds with the conserved residues (Ser93, Asn95 and
Ser105) which compose the ATP binding pocket (Fig. 2.2b). The ribose group of ATP
also binds to a water molecule and the backbone carbonyl group of Gln68 in Helix 1.
The adenosine group of ATP binds to the ATP binding pocket firmly; however, the
phosphate tail of ATP does not interact with any residues, consistent with its higher
temperature factor (B-factor > 60) and the poorly defined electron density in this region.
By comparing our crystal structure of MDDEF-ATP with the tertiary crystal
structure of MDD from Staphylococcus epidermidis (MDDSE-FMVAPP-ATPS, PDB
code: 4DPT), three major differences were observed in the phosphate binding loop (Fig.
2.2c) and the ATP/ATPS architecture (Fig. 2.2d). The phosphate binding loop in
MDDEF-ATP has not bent down, if compared with the phosphate binding loop in MDDSEFMVAPP-ATPS (Fig. 2.2c), which forms contacts with the -phosphate of ATPS
through hydrogen bonding (Table 1.1). Second, the -thiophosphate group of ATPS in
MDDSE-FMVAPP-ATPS was found to form contacts (hydrogen bonding) with the
backbone amide of two residues, S107 and A108, in Helix 2 (106-121), which are
located in the active site; instead, the -phosphate of ATP in our structure of MDDEF-ATP
is facing-out and does not interact with residues in Helix 2 in the active site (Fig. 2.2d).
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Third, the  and  phosphates in these two structures have been found to locate at
different positions and thus the orientation of the phosphate tails in these structures are
strikingly distinct (Fig. 2.2d).
The results from the multiple sequence alignment using EBI Clustal Omega82
show the primary sequences of MDDEF and MDDSE share 60% sequence identity (Table
2.2), and their active-site key residues involved in the substrate binding and catalysis are
conserved among the MDD family of proteins. Based on these observations, these two
homologous proteins are expected to catalyze the same reaction in a similar means. This
assumption leads to a hypothesis that the binding of another substrate, MVAPP, to the
active site might induce a change in the conformation for the binding of ATP to its
catalytically favored position. In the following chapters, we will be testing the hypothesis
through enzymatic, thermodynamic, and structural approaches.
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Figure 2.2 The superimposition of complex structures of MDDEF-ATP and MDD
from Staphylococcus epidermidis bound with FMVAPP and ATPS (MDDSEFMVAPP-ATPS). (a) A cartoon model of the crystal structure of MDDEF-ATP is shown
in pink and the ATP molecule as a stick model. (b) The ATP molecule is surrounded by
the ligand omit map (mFo-DFc at a contour of 2.5). Residues and waters (red spheres)
involved in the ATP binding are depicted. (c) An overlay of the cartoon models of
MDDSE-FMVAPP-ATPS (PDB: 4DPT, green) and MDDEF-ATP (pink) (r.m.s.d.
=0.663Å) are depicted with the phosphate binding loops emphasized (thickened lines).
(d) Ligands from the two structures are shown as stick models (FMVAPP and ATPS
from MDDSE-FMVAPP-ATPS; ATP and SO42- from MDDEF-ATP). The arrows in green
and pink indicated the distinct orientations of the phosphate tails of ATPS and ATP in
these two structures.

Table 2.2 Percent identity matrix of the MDD family of proteins
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2.5

Discussion

In 2012, Barta et. al. reported experimental findings on the substrate binding order
of MDDSE. Based on the geometric properties of the two substrate binding pockets, they
proposed the MDDSE substrate binding model belongs to an ordered bi-substrate
mechanism in which the MVAPP is the first substrate. However, a few issues remain
unsolved from their structural results. First, the 10-4 loop could not be determined in
their complex structure of MDDSE-FMVAPP-ATPS (Table 1.1). A conserved lysine in
this loop has not yet been annotated, although it was suggested to be important for
catalysis via mutagenesis study in MDD from rats58. Second, MDD proteins have been
known to trigger the ATP-dependent decarboxylation of MVAPP, but with a requirement
for metal ions (Mg2+) to perform catalysis under physiological conditions60. However, in
their structures, there is no structural evidence to suggest the location of metal binding
sites. Third, the thiophosphate group of ATPS, although in the active site, has been
found to be too far from the 3’-OH group of MVAPP (5.5 Å ) for catalysis (Table 1.1),
which has been proposed to be the phosphate acceptor during phosphoryl transfer from
ATP to MVAPP. Based on the observations above, we could argue that the structure
models of MDDSE were not complete and the substrate binding model for the MDD
family of proteins remains unestablished. In the future, this could also be a problem for
structure-based drug design which is heavily dependent on accurate atomic models of
macromolecules. Interestingly, ATP can also bind to the ATP binding pocket of MDDEF
alone in our structure of MDDEF-ATP. However, an outward facing phosphate tail of
ATP and the position of the phosphate binding loop indicate that the architecture of ATP
is not for enzyme catalysis, suggesting the binding of MVAPP might be a prerequisite
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step in the enzymatic reaction cycle. This actually encourages us to work on the
determination of the substrate binding model and the structures of unbound and ligandbound MDDEF.
Interestingly, in our crystal structure of MDDEF-ATP, the ATP molecule does not
have magnesium bound to the - and -phosphate group. In the crystallization condition,
we have 5 mM magnesium chloride and 10 mM ATP in the solution. The buffer condition
is 50 mM sodium acetate at pH 4.5 and the protonation state of ATP is mainly HATP3under this condition84. The dissociation constant between HATP3- and magnesium is
about 1.58 mM (log Ka = 2.79 ± 0.15)85, and the MgHATP concentration under this
condition is about 4 mM, suggesting the concentration of free HATP3- is about 6 mM.
The reason for not seeing magnesium-bound ATP in the crystal structure of MDDEF-ATP
could be due to the competitive binding of free HATP3- to the ATP binding pocket of
MDDEF, or a higher average of temperature factor of the phosphate tail of ATP (B) results
in poorly defined electron density in this region so that we cannot claim a magnesium ion
in this structure.
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CHAPTER 3. CHARACTERIZATION OF THE ENZYME KINETICS OF MDDEF

3.1

Chapter Summary

The crystal structure of MDDEF-ATP described in the previous chapter implied
that the binding of MVAPP cause changes in the protein that could affect the binding of
ATP. In previous work with avian MDD, the substrate binding order of MDD has been
suggested to be an ordered bi-substrate mechanism with MVAPP binding first72. In our
study, we wanted to know if the overall enzyme mechanism was conserved in the
bacterial enzyme MDD so that we could interpret the conformational changes upon
substrate binding observed in crystals of MDDEF in complex with different ligands. We
have done the enzymatic activity assays at varied concentrations of both substrates,
MVAPP and MgATP, to confirm that the MDDEF enzymatic reaction belongs to a
sequential bi-substrate mechanism. Then we utilized ATPS, an ATP analogue, to
determine that MVAPP is the first substrate bound based on the inhibitory pattern of
increasing ATPS in the reaction. With this information, we can now characterize the
conformational changes observed in MDDEF complex structures with an ordered
substrate/ligand binding event.

3.2

Introduction

MDD proteins trigger the decarboxylation of MVAPP to produce IPP and this
reaction is coupled with the conversion of ATP to ADP. Sequence and structure analysis
has suggested the two substrate binding pockets are conserved across the MDD family of
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proteins59,67. So far, several crystal structures of MDD proteins from prokaryotes and
eukaryotes have been determined and published in literature59,67,69. In a structure analysis
of the MDDSE in complex with different ligands, MVAPP is the first substrate bound
since its binding pocket is located more deeply in the active site of MDD than the binding
pocket of ATP59. One eukaryotic MDD protein from chicken was examined via
enzymology approaches few decades ago to determine the substrate binding order of
MDD; these results also suggested MVAPP is the first substrate72. However, from our
crystal structure of MDDEF-ATP, ATP can also bind to the ATP binding pocket by itself,
even if in an unproductive form (Fig. 2.2b). The question comes to us whether the
substrate binding order is conserved in both eukaryotic and prokaryotic MDD proteins.
The determination of the substrate binding order of MDDEF will allow us to design
experiments for obtaining the crystal structures of MDDEF in complex with ligands in an
ordered manner, and hopefully obtain structural snapshots of different states in the MDD
catalytic reaction. In order to achieve our goal, the first step is to establish the functional
assay for examining the MDDEF enzymatic function.
MDD proteins act on MVAPP and ATP to produce IPP, ADP, CO2 and PO42-.
Ideally, the activity can be directly measured by detecting the production of any of the
individual products. However, detecting the production of CO2 is not plausible for the
future high-throughput drug screening against MDDEF. Although free phosphate can be
detected via the malachite green assay method, in our preliminary tests, this method is not
sensitive when the phosphate concentration is more than 10 M. In addition, ATP in
solution is labile and undergoes hydrolysis under acidic conditions used in the malachite
green assay, which could severely affect the readout and results. As for the detection of
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IPP, high performance liquid chromatography (HPLC) has been used to separate IPP
from MVAPP and the method could not be transformed to HTS86.
In the literature, the coupled enzyme method (pyruvate kinase/lactate
dehydrogenase) has been widely used for monitoring ADP production, and this method
has also been applied for measuring the MDD enzymatic activity58,60,67 (Fig. 3.1). In this
assay, ADP produced from the MDD reaction is converted back to ATP by pyruvate
kinase, coupled with the conversion of phosphoenolpyruvate to pyruvate, and the
pyruvate is then converted to lactate by lactate dehydrogenase, coupled with the
oxidation of NADH to NAD+. The oxidation of NADH to NAD+ results in an absorbance
decrease at 340nm. Thus the ADP production can be detected by measuring the decrease
in OD340nm. The MDD enzymatic activity would be proportional to the slope of the
continuously declining value of OD340nm. We have utilized this method to determine the
enzymatic activity of MDDEF under different conditions for obtaining kinetic parameters
of MDDEF.
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Figure 3.1 The scheme of the PK/LDH coupled enzyme reaction. MDDEF performs
the ATP-dependent decarboxylation of mevalonate 5-diphospahte (MVAPP) to produce
isopentenyl diphosphate (IPP), carbon dioxide (CO2), phosphate and ADP. Magnesium
(Mg2+) is a cofactor that binds to ATP and ADP with a Kd value of 20 M85. The
PK/LDH coupled reaction serves as a reporting system for measuring the production of
ADP, which corresponds to the enzymatic rate of MDDEF. The decrease of absorbance at
340nm indicates the oxidation of NADH to NAD+, which is coupled with the
regeneration of ADP to ATP.
The MDD enzymatic reaction belongs to a bi-substrate mechanism, in which
MVAPP and ATP are its two substrates. Bi-substrate enzymatic reactions can be roughly
divided into two major categories: the ping-pong and the sequential bi-substrate
mechanisms, and the binding of two substrates in a sequential mechanism can be either
an ordered or random binding event. For a ping-pong bi-substrate reaction, the free
enzyme (E) will first act on the first substrate (A) to produce the first product (P), and the
intermediate form of the enzyme (E*) will further act on the second substrate (B) and
produce the second product (Q), followed by the next reaction (Fig. 3.2a). For studying
the enzyme kinetics, kinetic data will be represented by Equation 3.1, where v is a value
of determined enzyme activity under certain condition, [A] and [B] are the concentrations
of the two substrates, and Vmax, KmA and KmB are kinetic parameters. Kinetic data will be
analyzed and represented by Lineweaver-Burk plots, and an enzyme with a ping-pong bi-
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substrate reaction will show a parallel-line characteristic in a Lineweaver-Burk plot (Fig.
3.2b), and in this case, A will be the first substrate in a ping-pong reaction.

Equation 3.1

For a sequential random bi-substrate reaction, the free enzyme (E) can bind either of
two substrates (A or B) first; the first tertiary complex (E˙A˙B) will form followed by
catalysis, which results in the formation of the second complex (E˙P˙Q), where P and Q
are two products which can be released randomly (Fig. 3.3a). Kinetic data in this case
will be represented by Equation 3.2, analyzed by Lineweaver-Burk plots and the
simulated results are shown in Fig. 3.3b, in which kinetic lines in a Lineweaver-Burk plot
will converge to the x axis.

Equation 3.2
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Figure 3.2 Ping-Pong bi-substrate mechanism. (a) The scheme of a ping-pong bisubstrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b) Kinetic
data analyzed by a Lineweaver-Burk plot indicates a ping-pong bi-substrate mechanism,
where parallel lines represent kinetic measurements of the enzymatic activity at several
fixed concentrations of substrate B and varying concentrations of substrate A.

37

Figure 3.3 Sequential random bi-substrate mechanism. (a) The scheme of a sequential
random bi-substrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b)
Enzymatic reactions are conducted at several fixed concentrations of substrate B and
varying concentrations of substrate A. Kinetic data are represented by Equation 3.2 and
kinetic lines converging to the x axis in a Lineweaver-Burk plot.
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For a sequential ordered bi-substrate reaction, the enzyme (E) binds to the first
substrate (A), followed by the binding of the second substrate (B). The first tertiary
complex (E˙A˙B) will form and catalysis occurs and results in the formation of the
second complex (E˙P˙Q), where P and Q are two products, which could be released in an
ordered manner (Fig. 3.4a). For a rapid-equilibrium reaction, in which the enzyme
catalysis step is a rate-limiting step, kinetic data will be represented by Equation 3.3, and
kinetic lines converge to the y axis (Fig. 3.4b). For a steady-state reaction, in which the
velocity of enzyme catalysis is similar to that of substrate binding, the data will be
represented by Equation 3.4, and kinetic lines converge to x axis, similar to that in a
sequential random bi-substrate mechanism (Fig 3.4c).

Equation 3.3

Equation 3.4
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Figure 3.4 Sequential ordered bi-substrate mechanism. (a) The scheme of a sequential
ordered bi-substrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b)
For a rapid-equilibrium reaction, enzymatic reactions are conducted at several fixed
concentrations of substrate B and varying concentrations of substrate A. Kinetic data are
represented by Equation 3.4 and the Lineweaver-Burk plot analysis shows kinetic lines
converging to the y axis. (c) For a steady-state reaction, enzymatic reactions are
conducted at several fixed concentrations of substrate B and varying concentrations of
substrate A. Kinetic data are represented by Equation 3.5 and the Lineweaver-Burk plot
analysis shows kinetic lines converging to the x axis.
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Lineweaver-Burk plots of a reaction that belongs to the ping-pong mechanism
will yield a set of parallel lines, as seen in Figure 3.2b. Instead, if a reaction conforms to a
sequential mechanism, kinetic lines will converge in Lineweaver-Burk plots (Fig. 3.3b,
Fig. 3.4b and c). Thus, to differentiate the mechanism of a reaction, first of all, we would
need to perform a set of enzymatic reactions at varying concentrations of both substrates
and utilize the Lineweaver-Burk plotting method to analyze the data. Second, if the
mechanism of a reaction belongs to a sequential bi-substrate mechanism (except for a
rapid-equilibrium sequential ordered mechanism), the kinetic data will be represented by
the general equation for a bi-substrate system (Equation. 3.5), and we will need a
substrate analogue as a dead-end inhibitor to obtain inhibitory patterns and determine the
substrate binding order based on the patterns presented in Table 3.1. For example, if a set
of enzymatic reactions were performed for an enzyme at varied concentrations of both
substrates and the kinetic lines were shown to converge to the x axis in a LineweaverBurk plot, the enzyme mechanism of that particular enzyme belongs to a sequential bisubstrate mechanism; however, substrate binding events could be either random or
ordered. If A is suspected to be the first substrate in the reaction, a substrate analogue
mimicking B can be used in the inhibitory assays for obtaining unique patterns (varied
[A]: uncompetitive; varied [B]: competitive, Table 3.1). Using a substrate analogue
mimicking A in inhibitory assays will obtain inhibitory patterns (varied [A]: competitive;
varied [B]: noncompetitive, Table 3.1) similar to the inhibitory patterns in a sequential
random bi-substrate mechanism (Table 3.1). It should be mentioned that the inhibitory
patterns of a sequential ordered bi-substrate mechanism derived from the experiments
using a second substrate analogue as a dead-end inhibitor have no difference from the
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derived inhibitory patterns of a ping-pong bi-substrate mechanism, so it is required to
perform enzymatic reaction at varying concentrations of both substrates to differentiate
whether a mechanism belongs to a sequential or ping-pong bi-substrate reaction in the
beginning of the experiments.

Equation 3.5

Table 3.1 Patterns of dead-end inhibition of a bi-substrate reaction*
Mechanism

Competitive inhibitor
mimicking a substrate

Sequential ordered

Inhibition pattern**
Varied [A]

Varied [B]

A

Competitive

Noncompetitive

B

Uncompetitive

Competitive

A

Competitive

Uncompetitive

B

Noncompetitive

Competitive

Sequential random

A

Competitive

Noncompetitive

Sequential random

B

Noncompetitive

Competitive

Ping-Pong

A

Competitive

Uncompetitive

Ping-Pong

B

Uncompetitive

Competitive

with A binding first
Sequential ordered
with A binding first
Sequential ordered
with B binding first
Sequential ordered
with B binding first

*The table is modified from Table 11.2 in the text book “Enzymes: A Practical Introduction to
Structure, Mechanism and Data Analysis” edit by Robert A. Copeland87.
**The reactions would be conducted at a non-saturating concentration (about the Km value) of the fixed
substrate.
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3.3

3.3.1

Materials and Methods

Enzyme kinetics of wild type MDDEF
Enzymatic activity of MDDEF was determined using an ATP/NADH enzyme-

coupled assay. Each reaction was performed at 30℃ under the buffer condition (100 mM
HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 0.2 mM NADH, 0.4 mM
phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate dehydrogenase, and
100 nM MDDEF59). Initial velocity of each reaction was determined at a range of
concentrations of MgATP (50, 100, 150, 200, 400, 600, 800 and 1000 M) and MVAPP
(10, 15, 25, 50, 100, 150, 200 and 300 M). Enzymatic parameters, Km and Vmax, were
determined by fitting kinetic data to a sequential bi-substrate mechanism model using
SigmaPlot12.5/Enzyme Kinetic Module 1.3 (Systat Software, Inc.).

3.3.2

Inhibition assay
ATPS was used as a competitive inhibitor of ATP for determining the inhibition

kinetics of MDDEF. Different fixed concentrations of ATPS (0, 100, 200 and 400 M)
were added into the reactions versus varying MgATP (50, 100, 200 and 400 M) and
fixed MVAPP (40 M), or varying MVAPP (10, 20, 40, 80 M) and fixed MgATP (200
M). Assays were performed under the condition as described above. The kinetic data
with a fixed MVAPP concentration were fit into a competitive inhibition model; the
kinetic data with a fixed MgATP concentration were fit into an uncompetitive inhibition
model using SigmaPlot as previously described.
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3.4

Results

We have performed enzymatic reactions at varying concentrations of both
substrates of MDDEF, MgATP and MVAPP (Fig. 3.5a and c), and analyzed the kinetic
data by the Lineweaver-Burk method (Fig 3.5b and d). Each 1/v (reciprocal of reaction
velocity) was plotted as a function of either 1/[MVAPP] (reciprocal of varying
concentrations of MVAPP) (Fig. 3.5b) or 1/[MgATP] (reciprocal of varying
concentrations of MgATP)(Fig. 3.5d). The data were best represented by a sequential bisubstrate model using the general equation for a bi-substrate enzyme catalysis system
(Equation 3.5). The patterns in Figure 3.5b and Figure 3.5d show that the kinetic curves
in the double reciprocal plots converge to the x-axis. We could then confirm the enzyme
mechanism of MDDEF belongs to a sequential bi-substrate mechanism, but not a pingpong mechanism or a rapid-equilibrium sequential ordered mechanism. From the curve
fitting, we could then obtain kinetic parameters: Vmax = 16.1 ± 0.3 (mole/min/mg), kcat =
9.8 ± 0.2 (s-1), KmMVAPP = 39.7 ± 2.8 (M), KmMgATP = 166 ± 12 (M) (Table 3.2). We
will design experiments based on the KmMVAPP and KmMgATP values in the following
inhibitory assays
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Figure 3.5 Kinetic analysis of MDDEF. (a) A set of kinetic data at varying
concentrations of MVAPP and several fixed concentrations of MgATP ((●)50, (○)100,
(▼)200, (▽)400, (■)600, (□)800 and (◆)1000 M) is represented by a MichaelisMenten plot. (b) The same data set from (a) is represented by a Lineweaver-Burk plot. (c)
The same data set at varying concentrations of MgATP and several fixed concentrations
of MVAPP ((●) 10, (○) 15, (▼) 25, (▽) 50, (■) 100, (□)150, (◆) 200 and (◇) 300 M)
is represented by a Michaelis-Menten plot. (d) The same data set from (c) is represented
by a Lineweaver-Burk plot. Kinetic data are represented by Equation 3.5 used for a
sequential bi-substrate model. Each data point represents independent triplicate results
and the error bar for each point indicates standard deviations
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In the literature, either a product or substrate analogue has been utilized for
determining the substrate binding order of a given enzyme if it has more than one
substrate. To determine the substrate binding mechanism of MDDEF, we considered
whether to use either MVAPP analogues (such as DPGP or FMVAPP) (Fig. 3.6) or ATP
analogues (AMPPCP, AMPPNP or ATPS) as inhibitors (Fig. 3.7).

Figure 3.6 MVAPP and its analogues. DPGP: diphosphoglycolyl proline; MVAPP:
mevalonate 5’-diphosphate; FMVAPP: 6-fluoromevalonate pyrophosphate.
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Figure 3.7 ATP and its analogues. ATP: adenosine triphosphate; AMPPCP:
beta,gamma-Methylene ATP; AMPPNP: gamma-Imino-ATP; ATPS: gamma-Thio-ATP.
The differences between ATP and its analogues are emphasized and shown in red.

In the literature, MVAPP was identified as the first substrate based on the kinetic
study in MDD from chicken60 and the structural study in MDD from Staphylococcus
epidermidis59. We hypothesized that if MVAPP were the first substrate followed by the
ATP binding, we would need to use ATP analogues as dead-end inhibitors to obtain the
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unique inhibitory patterns; to use MVAPP analogues would not provide solid results for
us to differentiate an ordered binding mechanism from a random binding mechanism
(Table 3.1). AMPPCP and AMPPNP are two ATP analogues commonly used in kinase
studies. The difference between these two analogues and ATP is the replacement of the
bridging oxygen between the - and -phosphate of ATP to either the CH2 group for
AMPPCP or the NH group for AMPPNP (Fig. 3.7). It is known that AMPPCP and
AMPPNP are weak inhibitors for MDD (Ki > 1mM)72, showing these two molecules are
not suitable to be utilized in the inhibitory assays. Instead, ATPS (Fig. 3.7) has been
shown to inhibit the enzymatic activity of MDD from chicken with a Ki value of about
200 M72. Although ATPS can be an alternative substrate for some kinases88, it is fairly
stable in our reaction system (suggested from our ITC experiments in the following
chapter). Thus we could consider it as a dead-end inhibitor against MDDEF in this study.
According to Table 3.1, we would need to perform two sets of experiments with
the addition of varying concentrations of ATPS in the reactions to determine the detailed
substrate binding mechanism of MDDEF. The first set of experiments was performed at a
constant MVAPP concentration of 40 M (about the KmMVAPP value: 39.7 M), and
varying concentrations of MgATP (100, 150, 200, 400 M) and ATPS (0, 100, 200, 400
M). Under this condition, the kinetic data set best fit a competitive inhibition model as
described by Equation 3.6, where Vmax is the maximum velocity; [B] is the varying
concentrations of ATP; KB is KmMgATP; KiA is KdMVAPP; KA is KmMVAPP; KiA/KA is 0.8
which was derived from the general equation describe above; [I] is the varying
concentrations of ATPS, and Ki is KiATPS. The kinetic data from the inhibitory assays
were represented by a Mechaelis-Menten plot (Fig. 3.8a) and a Lineweaver-Burk plot
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(Fig. 3.8b) and the inhibition pattern in this case belongs to a competitive inhibition
pattern. The values of Vmax, KmMgATP and KiATPS were derived from Equation 3.6 and are
summarized in Table 3.2.

Equation 3.6

The second set of experiments was performed at a constant MgATP concentration
of 200 M (about the KmMgATP value: 166 M), and varying concentrations of MVAPP
(10, 20, 40, 80 M) and ATPS (0, 100, 200, 400 M). Each data point represents
independent triplicate results and the error bar for each point indicates standard
deviations. The data set was best represented by an uncompetitive inhibition model using
Equation 3.7, where Vmax is the maximum velocity; [I] is the varying concentrations of
ATPS, and Ki is KiATPS; KiA is KdMVAPP and KA is KmMVAPP; KiA/KA is 0.8 which was
derived from the general equation describe above; [A] is the varying concentrations of
MVAPP. The kinetic data from the inhibitory assays were represented by a MechaelisMenten plot (Fig. 3.8c) and a Lineweaver-Burk plot (Fig. 3.8d) and the inhibition pattern
in this case belongs to a competitive inhibition pattern. The values of Vmax, KmMVAPP, and
KiATPS were also derived from Equation 3.7 and are summarized in Table 3.2.
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Equation 3.7

Figure 3.8 Inhibitory assays of MDDEF. (a) Different fixed concentrations of ATPS
((●) 0, (○) 100, (▼) 200 or (▽) 400 M) were added to the reactions at a fixed
concentration of MVAPP (40 M) and varying concentrations of MgATP (100, 150, 200
or 400 M). The set of inhibitory data is represented by a Michaelis-Menten plot. (b) The
same set of data from (a) is represented by a Lineweaver-Burk plot. (c) Different fixed
concentrations of ATPS ((●) 0, (○) 100, (▼) 200 and (▽) 400 M) were added to the
reactions at a fixed concentration of MgATP (200 M) and varying concentrations of
MVAPP (10, 20, 40 and 80 M). The set of inhibitory data is represented by a MichaelisMenten plot. (d) The same set of data from (c) is represented by a Lineweaver-Burk plot.
(a) and (b) are represented by a competitive inhibition model; (c) and (d) are represented
by an uncompetitive inhibition model. The means and the standard deviation of each data
point were obtained from a triplicate test. Each data point represents independent
triplicate results and the error bar for each point indicates standard deviations
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We have performed classical enzymatic reactions at varying concentrations of
MgATP and MVAPP. The initial kinetic data for MDDEF best fit a sequential bi-substrate
mechanism. Two sets of data from the inhibitory assays using the second substrate
analogue, ATPS, were also in agreement with an ordered bi-substrate mechanism. At a
fixed concentration of the first substrate, MVAPP, we observed a competitive inhibition
pattern by varying the concentrations of MgATP and ATPS in the reactions; at a fixed
concentration of the second substrate, MgATP, we observed an uncompetitive inhibition
pattern by varying the concentrations of MVAPP and ATPS in the reactions. From the
observation of inhibitory results, we therefore suggest that MDDEF binds to its two
substrates, MVAPP and MgATP, in an ordered fashion with MVAPP binding first, and
the sequential ordered bi-substrate mechanism may be conserved among the MDD family
of proteins.

Table 3.2 Enzyme kinetic parameters*
Vmax

Vmax

kcat

KmMVAPP

KmMgATP

KiappATPS

Inhibition
Metal

(s-1)

(mole/min/mg)

(M/s)

16.1 ± 0.3

0.75 ± 0.02

9.8 ± 0.2 39.7 ± 2.8 166 ± 12

20.4 ± 0.8

0.94 ± 0.04

12.4 ± 0.6 42.6 ± 3.4

24.0 ± 0.6

1.12 ± 0.2

14.6 ± 0.4

*

(M)

-

(M)

Pattern

(M)
-

Mg2+

-

173 ± 16

Mg2+ Uncompetitive

165 ± 9

199 ± 13

Mg2+ Competitive

The means and the standard deviation of each data point were obtained from a triplicate test (Means

± the standard deviation)
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3.5

Discussion

In the literature, there are two MVAPP analogues, 6-fluoromevalonate 5diphosphate (FMVAPP) and diphosphoglycolyl proline (DPGP), that compete the
binding of MVAPP and show inhibitory potency against MDD from humans (KiFMVAPP =
0.062 M, KiDPGP = 2.3 M)69 and Staphylococcus epidermidis (KiFMVAPP = 0.049 M,
KiDPGP = 4 M)67. It has been also suggested that these two compounds can effectively
inhibit the MDD family of proteins due to the conserved features of MVAPP binding
pocket in the active site across MDDs. However, in this study, MVAPP analogues could
not be utilized for determining the substrate binding order because the derived inhibitory
patterns would not be conclusive for differentiating whether the binding mechanism of
MDDEF belongs to a sequential ordered or random bi-substrate mechanism (Table 3.1).
The second substrate analogue can be utilized since the derived inhibitory patterns are
unique. At a constant concentration of MVAPP and varying concentrations of MgATP
and ATPS, the results show a competitive inhibition pattern since ATPS can bind to the
ATP binding pocket59 and compete with ATP. At a fixed concentration of MgATP and
varying concentrations of MVAPP and ATPS, the results best fit an uncompetitive
inhibition model. The feature of uncompetitive inhibition is that an inhibitor can enhance
the substrate binding and simultaneously reduce the enzymatic rate. From structural
points of view, the ATP binding pocket of MDD locates right above the MVAPP binding
pocket, suggesting the binding of ATPS may block the dissociation of MVAPP from
MDDEF, and thus the inhibitory pattern shows uncompetitive and decreasing apparent
KmMVAPP when increasing ATPS concentrations (Fig. 3.8d).
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Sequential ordered bi-substrate mechanisms can be further classified into rapidequilibrium, steady-state and Theorell-Chance mechanisms. Our kinetic studies (Fig. 3.5)
shows the reaction is not a rapid equilibrium ordered mechanism, meaning the chemical
steps in the MDDEF reaction are not rate-limiting if compared with the substrate binding
and product release. However, the inhibition patterns derived from our inhibitory assays
would not allow us to determine if the reaction is either a steady-state or a TheorellChance mechanism. Although the first priority in this study is to determine the substrate
binding order of MDDEF, in the future, we will need to perform enzymatic reactions using
alternative substrates or product inhibition strategies at both saturated and unsaturated
concentrations of MVAPP and MgATP89 to comprehensively investigate the overall
enzyme mechanism of MDDEF.
From the kinetic study on MDDEF, MVAPP is suggested to be the first substrate
in the reaction. Our first crystal structure of MDDEF in complex with ATP showed that in
the absence of MVAPP, ATP binds the ATP binding pocket in an unusual configuration
(Fig. 2.2d) and the phosphate binding loop does not bend down to interact with the ATP
molecule (Fig. 2.2c). These results suggest MVAPP has to bind to the active site in the
first step of the reaction, and also imply the binding of MVAPP may cause
conformational changes that re-shape the ATP molecule and the phosphate binding loop
to their catalytically favored configuration. An ATP molecule in a favored configuration
in the active site may be a stronger binder than one in an unusual configuration. In other
words, the binding of MVAPP might induce conformational changes which facilitate the
binding of ATP.
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CHAPTER 4. THERMODYNAMIC STUDIES ON MDDEF BY ISOTHERMAL
TITRATION CALORIMETRY SUGGEST A SUBSTRATE-INDUCED
SUBSTRATE BINDING MECHANISM FOR MDDEF

4.1

Chapter Summary

The structural information from MDDEF-ATP and the MDDEF enzyme kinetics
results suggest that the pre-binding of MVAPP could induce conformational
rearrangements of MDDEF and thus enhance the ATP binding. To further test this, we
employed thermodynamic approaches and utilized isothermal titration calorimetry (ITC)
to determine the dissociation constants of first substrate, MVAPP, second substrate,
MgATP, and ATP analogues, ATPS and AMPPCP. Our results were in agreement with
our proposed model, in which the binding of ATPS was enhanced by the prerequisite
binding of MVAPP to MDDEF, suggesting the binding of MVAPP would accommodate
the ATP molecule in its catalytically favored position for the following chemical steps in
the reaction.

4.2

Introduction

Our experimental evidence suggests that the binding of MVAPP will affect ATP
binding. From our kinetic study, the enzyme mechanism belongs to a sequential ordered
bi-substrate mechanism with MVAPP binding first; the crystal structure of MDDEF-ATP
showed an unusual ATP configuration. We would then hypothesize that the binding
affinity of ATP to MDDEF might be enhanced by the prerequisite binding of MVAPP. To
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better understand these binding events, we introduced thermodynamic approaches into
our research. So far, there are no substrate analogues exhibiting distinguishing changes in
absorbance or fluorescence signals upon binding to MDDEF. Therefore, isothermal
titration calorimetry (ITC) was employed in this study to measure thermodynamic
changes without modification or immobilization of MDDEF proteins or its ligands during
the protein-ligand interactions90.
The main concept of the ITC technique is to detect heat changes in a system when
macromolecule-ligand binding events take place. In the design of ITC, the temperature of
the reference cell and the sample cell are controlled and monitored. The reference cell is
filled with either buffer or water, and the sample cell is filled with either macromolecules
or ligands depending on the experimental design. The injection syringe is filled with the
titrant of interest which is then injected into the sample cell (Fig. 4.1a). The two binding
partners in the sample cell will form a complex either resulting in heat absorption
(endothermic reaction) or release (exothermic reaction), and the heat difference between
the reference cell and the sample cell will be monitored overtime (Fig. 4.1b). Because the
temperature has been set to be the same in these two cells, the ITC instrument will adjust
the power input to the sample cell to maintain the temperature. Once the data have been
collected (Fig. 4.1c), the heat changes per injection (area under or above the baseline)
will be calculated to generate a thermogram, in which the heat of injection in kcal/mole is
plotted as a function of molar ratio of ligand/macromolecule in the sample cell (Fig.
4.1d). After curve fitting, the thermodynamic parameters, stoichiometry (n), binding
constant (Ka) and enthalpy (H) can be derived. The Gibbs free energy (G) can then be
calculated from Ka, and entropy (S) can be further derived.
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Figure 4.1 Background of ITC. (a) A cartoon figure showing the ITC instrument
containing a reference cell, and a sample cell, and a syringe with a titrant (yellow) which
can be injected into the sample cell for the following titrations. (b) An ongoing
thermogram (black line) with illustrations of macromolecule-ligand binding
(macromolecules in blue and ligands in red) at the top. The heat of the binding reaction is
released (exothermic). (c) A complete thermogram (black line) with the calculated
baseline (red line). (d) The ITC data were processed and the heat changes were plotted as
a function of the molar ration of ligand to macromolecule. The binding constant (Ka),
stoichiometry (n) and enthalpy (H) can be derived from curve fitting. Ka is related to the
slope (red dash).
In order to test if the binding of MVAPP can enhance the strength of ATP binding,
we want to determine the dissociation constant Kd (1/Ka). This can be achieved using
either a catalytically dead mutant of MDDEF or stable substrate analogues (FMVAPP,
ATPS, etc.). In the literature, it has been suggested that Asp283 of MDDSE in the active
site serves as a catalytic residue for de-protonizing the 3’-OH group of MVAPP, followed
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by the phosphoryl transfer of ATP -phosphate and spontaneous decarboxylation to yield
isopentenyl diphosphate (IPP) (Fig. 4.2)91.
Although the dead mutant of MDDSE (D283A) has non-detectable enzymatic
activity, we found that this D-to-A mutant would not be suitable for thermodynamic study
and the determination of KdATP values because MVAPP appears to bind in different ways
in the wild type and the mutant of MDDSE. Two structures, MDDSE in complex with
FMVAPP and ATPS (MDDSE-FMVAPP-ATPS, PDB: 4DPT) and a D283A mutant of
MDDSE in complex with MVAPP and ATPS (D283A-MVAPP-ATPS, PDB: 4DPW),
were superimposed (Fig. 4.3a) with an r.m.s.d. value of 0.47Å. However in D283AFMVAPP-ATPS, the conformation of MVAPP is different from FMVAPP in MDDSEFMVAPP-ATPS and it no longer interacts with Arg144, if compared with FMVAPP in
MDDSE-FMVAPP-ATPS (Fig. 4.3b). This suggests that Asp283 may also play a role in
the binding of MVAPP which could then change its effect on ATP binding, since the
conformation of phosphate tails of ATPS in these two structures are also different (Fig.
4.2b). Therefore, the D-to-A mutant may not be suitable to determine Kd values of
ligands/substrates. In this situation, we will need to use wild type proteins and inactive
analogues for mimicking the binding event in catalysis. From our enzymology study,
ATPS can inhibit MDDEF enzymatic activity, so it is expected that ATPS can also bind
MDDEF. Here we will test if MVAPP assists in ATPS binding i.e. we would like to
examine if the Kd value of ATPS decreases when MDDEF is pre-incubated with MVAPP.
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Figure 4.2 The role of Asp283 in the proposed mechanism of the MDDSE enzymatic
reaction.
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Figure 4.3 Superimposition of two tertiary crystal structures of MDD from S.
epidermidis (4DPT) and its mutant, D283A (4DPW). (a) The overlay of the two
tertiary structures of the wild type MDDEF (pink) and the D283A mutant (green) in
complex with their ligands. The r.m.s. deviation of these two structures (excluding the
ligands) was calculated to be 0.47 Å. (b) The active-site ligand architecture in these two
structures. A283 and MVAPP from the D283A mutant are depicted and colored in green;
D283 and FMVAPP in pink are from wild type MDDSE; common features, R144 and
ATPS, are indicated (black text).
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4.3

4.3.1

Materials and Methods

Isothermal titration calorimetry (ITC) experiments
The preparation of TEV-treated MDDEF was described in the previous chapter.

The protein solution was dialyzed against buffer which is the same as used in the
enzymatic reactions described previously (100 mM HEPES, pH 7, 100 mM KCl and 10
mM MgCl2). All the buffer solutions in ITC experiments were filtered through 0.45 m
filter and degassed for 1 hour at room temperature. The protein concentration was
adjusted to 100 M (260 l). Each ligand (MVAPP, ATP, AMPPCP and ATPS) was
prepared in the same dialysis buffer to avoid buffer mismatch. The concentration of each
titrant was optimized in different experiments based on the experimental designs
simulated using the MICROCAL ORIGIN 7.0 software package, and the final concentration of
each ligand was adjusted to 2 or 3 mM. The ITC instrument, MicroCal iTC200, was
employed for isothermal titrations in this study and the reference cell was filled with
ddH2O containing 0.01% sodium azide. The experimental temperature was set at 25℃.
Each experimental profile composed of the addition of an initial aliquot of 0.4 l,
followed by 22 aliquots of 1.8 l of the substrate or ligand solution. The time interval
between two consecutive injections was 180 seconds. The data were further processed
with NITPIC92 and analyzed using an one-site model in SEDPHAT93. Figures were
generated using GUSSI in SEDPHAT.
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4.3.2

Analysis of ITC data
For a simple 1-to-1 binding event, the thermograms were obtained after titrations

and the stoichiometry n, enthalpy H and the binding constant Ka can be derived from the
curve fitting to the simple 1-to-1 binding mode (Equation 4.1) by Marquardt nonlinear
least square analysis.

2

Qi =

1
2

[L]t
[L]t
n[M]t∆HV0
1
1
4[L]t
{1 +
+
− [(1 +
+
) −
] }
2
n[M]t nKa[M]t
n[M]t nKa[M]t
n[M]t
Equation 4.1

In Equation 4.1, n represents the stoichiometry number, H enthalpy, Ka the binding
constant, [M]t the concentration of macromolecules in the sample cell, and [L]t the
concentration of a certain ligand in the sample cell. In each injection, the heat changes
(Qi = Qi – Qi-1) from new complex formation were measured. After curve fitting, Ka (1/
Kd), n and H can be derived. Another thermodynamic parameter, entropy (S) can be
obtained from the Gibbs free energy (G) of binding shown in Equation 4.2, where G is
the Gibbs free energy, R is the gas constant (8.314 J mol-1K-1) and T is the temperature in
Kelvin.

∆𝐺 = −𝑅𝑇lnKa = ∆𝐻 − 𝑇∆H
Equation 4.2
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4.4

Results

For designing ITC experiments, the ligand concentration in the syringe would be
about 10-fold greater than the concentration of macromolecules in the sample cell, so that
the molar ratio of ligand/macromolecule in the x-axis of a thermogram will end up at 2
for a 1-to-1 binding mode and the thermogram will ideally look like a sigmoid curve. In
Equation 4.1, the term “nKa[M]t” is referred to the “C” value, which is an indication for
experimental designs. In general, the C value is suggested to be in a range between 10 to
1000, in which H and Kd (1/Ka) can be accurately obtained. A lower C value (C < 10)
will result in a flat curve, which may not be useful for deriving thermodynamic
parameters; and a higher C value (C > 3000) will result in an inaccurate Kd (1/Ka) value
after curve fitting (Fig. 4.4).
In this study, the binding of ATP or ATP analogues to MDDEF was determined
weak (200 to 300 M, C = 0.2 to 0.3), and the heat changes upon binding were not huge.
Instead of increasing the protein concentration in the sample cell to obtain a better
titration experiment, we increased the ligand concentration in the syringe to increase the
heat changes per injection so that we could obtain more accurate thermodynamic
parameters and compare those results different ITC results.

62

Figure 4.4 Simulation of ITC thermograms. H is set at 10, and the binding is one-toone. The concentration of macromolecules is 100 M; the concentration of ligands is set
at 1 mM. The “C” value is equal to n*Ka*[M]t described above. Heat changes are plotted
as a function of the molar ratio of ligand to macromolecule.
We have performed several ITC experiments for determine the Kd values of
substrates or ligands (MVAPP, ATP and ATP analogues, AMPPCP and ATPS). The raw
data for titrations of wild type MDDEF are shown in Figure 4.5. All the derived
thermodynamic parameters, Kd (1/Ka), are listed in Table 4.1. First, we have performed
experiments to determine the Kd values between MDDEF and each substrate/analogue,
MVAPP, ATP, AMPPCP or ATPS. The KdMVAPP value is 20.4 ± 9.3 M; the KdATP value
is 288 ± 36 M; the KdATPS value is 215 ± 8 M (Fig. 4.5a, b, c and Table 4.1 row a, b,
c). Second, we performed ITC experiments to determine the KdATPS values under the
condition where MDDEF was pre-incubated with MVAPP. To assure that the MVAPP
binding pocket of MDDEF was nearly fully-occupied (more than 90%) with MVAPP, we
used a MVAPP concentration of 1 mM. According to the KdMVAPP value (20.4 ± 9.3 M)
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derived from the previous ITC experiment, the concentration of the MDDEF-MVAPP
complex ([MDDEF-MVAPP]complex, represented as 𝑥 in Equation 4.3) can be calculated
based on the total concentration of MDDEF ([MDDEF]total) and the total concentration of
MVAPP ([MVAPP]total) using Equation 4.3.

𝐾d =

([MDDEF]total − 𝑥)([MVAPP]total − 𝑥)
[MDDEF-MVAPP]complex
Equation 4.3

In our ITC experiment, [MVAPP]total was set at 1 mM, which was ten-fold greater
than [MDDEF]total (100 M). Using Equation 4.3, the [MDDEF-MVAPP]complex was
approximately calculated to be 97.8 M, meaning MDDEF was about 97.8%-saturated
with MVAPP in the system. Under these conditions, the Kd value between ATPS and
MDDEF-MVAPP was determined to be 25.4 ± 5.5 M (Fig. 4.5d and Table 4.1, row d),
which was ten-fold less than the Kd value between ATPS and MDDEF alone (Fig. 4.5c
and Table 4.1, row c), supporting our proposed model in which the pre-binding of
MVAPP would strengthen ATPS binding.
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Figure 4.5 The original titration curves from ITC experiments with MDDEF. (a)
MDDEF (100 M) titrated with MVAPP (2 mM). (b) MDDEF titrated with ATP (3 mM).
(c) MDDEF titrated with ATPS (3 mM). (d) MDDEF pre-incubated with MVAPP (1 mM)
and then titrated with ATPS (2 mM). The protein concentration is adjusted to 100 M
and all the protein and titrants are dissolved in the buffer containing 100 mM HEPES, pH
7, 100 mM KCl and 10 mM MgCl2.
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Table 4.1 Thermodynamic parameters*

Species

Substrate

Kd
(µM)

MVAPP
20.4 ± 9.3
(2 mM)
ATP
b MDDEF (100 M)
288 ± 36
(3 mM)
ATPγS
c MDDEF (100 M)
215 ± 8
(3 mM)
d MDDEF (100 M) + ATPγS
25.4 ± 5.5
(2 mM)
MVAPP (1 mM)
*Titration experiments were done at 25℃.
a MDDEF (100M)

ΔG**
(kcal/mol)

ΔH
(kcal/mol)

-6.5 ± 0.3

-0.7 ± 0.1

5.8 ± 0.2

19.5 ± 0.5

-4.8 ± 0.1

-3.8 ± 0.5

1.0 ± 0.3

3.5 ± 1.0

-5.00 ± 0.02

-6.4 ± 0.3

-1.4 ± 0.2

-4.7 ± 0.6

-6.3 ± 0.1

-4.8 ± 1.1

1.5 ± 0.6

5.0 ± 2.1

** The mean of ΔG () is derived from the equation: μ = −RTln (

𝑚
√1+

ΔG () is calculated from the equation: σ = √ln (1 +

𝑣
𝑚2

𝑣
𝑚2

TΔS#
ΔS
(kcal/mol) (cal/mol*K )

) and the standard deviation of

), where m is the mean of the association

constant (Ka) and v is the variance of Ka derived from each ITC experiment.
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2) and
the standard deviation () of TS is derived from the equation: 𝜎1−2 = √

𝜎1 2
𝑛

+

𝜎2 2
𝑛

, where 1 is the

standard deviation of G and 2 is the standard deviation of H.

4.5

Discussion

We assumed that MVAPP could also induce changes needed for enhanced ATP
binding to MDDEF. And the thermodynamic results are in agreement with our previous
observations in enzyme kinetics and the crystal structure of MDDEF-ATP. In addition to
the examination of changes of KdATPS in the presence of excess amounts of MVAPP in
the solution, we also tested whether this enhanced binding event occurs using AMPPCP.
The KdAMPPCP value was 271 ± 43 M (Fig. 4.6a and Table 4.2 row a); however, in the
presence of MVAPP, we could not detect heat changes and so could not obtain the
thermodynamic parameters in this case (Fig. 4.6b and Table 4.2 row b). When MDDEF
was pre-incubated with excess amounts of AMPPCP (10-fold, MDDEF-AMPPCP
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complex formation rate: 77.4%) and then the mixture was titrated with MVAPP (Fig. 4.6c
and Table 4.2 row c), the KdMVAPP value in this case is 18.7 ± 7.4 M, which is a similar
value as from the MDDEF-MVAPP titration (Fig. 4.5a and Table 4.1 row a); we have also
a preliminary test on ATPS. MDDEF was pre-incubated with excess amounts of ATPS
(10-fold, MDDEF-ATPS complex formation rate: 81.1%) and then the mixture was
titrated with MVAPP (Fig. 4.6d and Table 4.2 row d). The thermogram shows an unusual
two-process binding event and the titration ended after the 6th injection, suggesting a tight
binding event occurs. KdMVAPP was roughly determined to be 76nM (data not shown).
Although there are no other experimental results to explain the two-process binding, a
quick saturation after the 6th injection indicates that MVAPP binds MDDEF-ATPS much
tighter than MVAPP binds MDDEF alone (Fig. 4.5a and Table 4.1 row a). It also implies
that AMPPCP might not “lock” MVAPP in the active site and thus not affect the release
of MVAPP. We will discuss more structural evidence in the following chapter.
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Figure 4.6 The original titration curves from ITC experiments with MDDEF. (a)
MDDEF (100 M) titrated with AMPPCP (3 mM). (b) MDDEF pre-incubated with
MVAPP (1 mM) and then titrated with AMPPCP (5 mM). (c) MDDEF pre-incubated with
AMPPCP (1 mM) and then titrated with MVAPP (2 mM). (d) MDDEF pre-incubated with
ATPS (1 mM) and then titrated with MVAPP (2 mM). The protein concentration is
adjusted to 100 M and all the protein and titrants are dissolved in the buffer containing
100 mM HEPES, pH 7, 100 mM KCl and 10 mM MgCl2.
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Table 4.2 Thermodynamic parameters*

Species
a MDDEF (100 M)
b MDDEF (100 M) +
MVAPP (1 mM)
c MDDEF (100 M) +
AMPPCP (1 mM)
d MDD (100 M) +
EF

ATPS (1 mM)

Substrate
AMPPCP
(3 mM)
AMPPCP
(5 mM)

Kd
(µM)
271 ± 43

ΔG**
ΔH
(kcal/mol) (kcal/mol)
-4.87 ±
-3.20 ± 0.50
0.09

NDB

NDB

NDB

MVAPP
(2 mM)

18.7 ± 7.4

-6.50 ±
0.23

0.91 ± 0.18

MVAPP
(2 mM)

2 binding
process

-

-

TΔS#
ΔS
(kcal/mol) (cal/mol*K )
1.67 ± 0.36 5.61 ± 1.21
NDB

NDB

7.41 ± 0.20 24.88 ± 0.69
-

-

*Titration experiments were done at 25℃.
** The mean of ΔG () is derived from the equation: μ = −RTln (

𝑚
√1+

of ΔG () is calculated from the equation: σ = √ln (1 +

𝑣
𝑚2

𝑣
𝑚2

) and the standard deviation

), where m is the mean of the association

constant (Ka) and v is the variance of Ka derived from each ITC experiment.
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2)
and the standard deviation () of TS is derived from the equation: 𝜎1−2 = √
is the standard deviation of G and 2 is the standard deviation of H.

𝜎1 2
𝑛

+

𝜎2 2
𝑛

, where 1
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CHAPTER 5. CRYSTAL STRUCTURES OF THE APO AND LIGAND-BOUND
FORMS OF MDDEF PROVIDE SNAPSHOTS OF THE MDD ENZYMATIC
REACTION

5.1

Chapter Summary

In this chapter, we will discuss the conformational changes of MDDEF upon
substrate binding in an ordered manner. From the previous enzymology study, MVAPP
was determined to be the first substrate, and MVAPP has also been suggested to induce
structural rearrangements for the accommodation of the second substrate, MgATP, based
on the thermodynamic evidence. The previous condition used for MDDEF-ATP
crystallization was not suitable for growing the crystals of apo-MDDEF, so we started
over with crystallization screening and obtained a stable condition for constantly
producing apo-form MDDEF crystals. We exchanged the crystallization buffer with the
soaking buffer for the ligand soaking experiments. By doing that, we were able to obtain
MDDEF crystals in complex with ligands (MVAPP, AMPPCP, ADP, BeF3-, Mg2+) for the
steps in the reaction that these complexes represent (MDDEF-MVAPP, MDDEF-MVAPPAMPPCP-Mg2+ and MDDEF-MVAPP-ADPBeF3-Mg2+). From those structures, we
observed intriguing conformational changes in five regions of MDDEF: the phosphate
binding loop, the 10-4 loop, Helix 1, 2 and 4. We have also confirmed that there
are two metal binding sites during catalysis by detecting the anomalous signals from
cobalt in the complex structure of MDDEF bound with ADP-SO42- and Co2+ (MDDEFMVAPP-ADP-SO42--Co2+). These new findings allow us to propose detailed models for

70
elucidating the MDDEF substrate binding mechanism and enzyme catalysis. From the
substrate binding model, we identified possible drug targeting areas for the future specific
drug design.

5.2

Introduction

In 2012, the substrate binding mechanism of the MDD family of proteins was
proposed based on the structural observation from the apo-enzyme (4DPX) and ligandbound structure of MDDSE (4DU7: MDDSE-MVAPP; 4DPT: MDDSE-FMVAPP-ATPS)
in which only the phosphate binding loop was identified to be involved in substrate
accommodation59. However, the 10-4 loop (183-192) near the active site was undetermined due to poor electron density maps around this area. In this loop region, one
conserved lysine residue (Lys189 in MDDSE and Lys187 in MDDEF) has been suggested
to be pivotal for the enzyme activity, yet its role is unrevealed. Metal ions, specifically
Mg2+, have been known to be involved in catalysis60; however, the metal binding site(s)
in the MDD structures were also not defined. These observations imply that the published
structural models are still insufficient for elucidating substrate binding and catalytic
mechanisms of the MDD family of proteins and that the ligand architectures in the
complex structures may be still questionable.
Another problem with obtaining ligand-bound forms of MDD is the strong
tendency of this protein to bind sulfate/phosphate. MDD from Legionella pneumophilia
(3LTO), MDD from Mus musculus (3F0N), and MDD from Homo sapiens (3D4J)69 have
been crystallized under conditions containing sulfate or phosphate ions. In all three cases,
sulfate or phosphate has been shown to occupy a part of the MVAPP binding site and thus
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compete with substrate binding. Higher concentrations (> 200 mM) of these two ions
hamper the binding of MVAPP and thus ligand soaking experiments failed in the case of
MDD from Homo sapiens (3D4J)69. We initially obtained stable crystals under the
condition containing 1.45M of ammonium sulfate and in our preliminary results ligands
could not compete with sulfate binding in the active site (data not shown). Here we also
describe experimental strategies to overcome the sulfate/phosphate problem and still
maintain protein crystals in the same space group, P21212, so that several substrate
complex structures of MDDEF structures can be compared.

5.3

5.3.1

Materials and Methods

Protein crystallization, crystal soaking and cryo-protection procedures
A stable condition (1.6 M ammonium sulfate, 50 mM sodium acetate, pH 4.6) for

growing crystals was obtained and optimized from a commercialized crystallization
screening kit (Qiagen, Class II, condition A2: 0.1M sodium acetate, pH 4.5, 2M
ammonium sulfate). Protein solution (8 to 9 mg/ml) was mixed with the reservoir
solution at an 1:1 ratio and equilibrated by vapor diffusion of sitting drops at 20 ℃ for
two days. In a 96-well plate, there were about 20 wells containing single cuboid crystals
with a size of 0.2 to 0.3 mm. To perform buffer exchange for ligand soaking experiments,
the crystallization buffer surrounding protein crystals was replaced by soaking buffer (26
% PEG3350, 5 mM MgCl2, 50 mM sodium acetate, pH 4.6) and crystals were then
equilibrated in soaking buffer for 10 minutes. Each ligand was dissolved in soaking
buffer to a final concentration of 2 mM and a small amount of ligand solution (0.12 to
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0.15 l) was added into the drop for a one-day soaking procedure. For cryo-protection,
dehydration buffer (30 % PEG 3350, 15 % PEG400, 50 mM sodium acetate, pH 4.6) was
placed into the bottom well of each individual chamber in order to increase the PEG3350
concentration in the sitting drop. Crystals of MDDEF soaked with ligands and metal ions
were labeled in a manner of “MDDEF-ligand-metal”. Crystals with or without ligands
(MDDEF-SO42-, MDDEF-MVAPP, MDDEF-MVAPP-ADP-SO42--Co2+, MDDEF-MVAPPAMPPCP-Mg2+, and MDDEF-MVAPP-ADPBeF3-Mg2+) were obtained and frozen and
stored in liquid nitrogen after the dehydration process.

5.3.2

Data collection, structure determination, refinement analysis, refinement
statistics, and substructure determination
The diffraction data of the crystals described above as MDDEF-SO42-, MDDEF-

MVAPP, MDDEF-MVAPP-ADP-SO42--Co2+ were collected at the 23-ID-D beamline at
Advanced Photon Source (APS) at Argonne National Laboratory in Chicago. Diffraction
data of the other two crystals (MDDEF-MVAPP-AMPPCP-Mg2- and MDDEF-MVAPPADPBeF3-Mg2+) were collected on the home-source X-ray diffraction equipment. The
phases for determining crystal structures of MDDEF with ligands were solved by
molecular replacement in Phenix.phaser76 using the protein structure of MDDEF-ATP in
our previous chapter as a search model. The structural files of ligands (MVAPP, ADP,
SO42-, Mg2+, Co2+, BeF3-, and AMPPCP) were obtained from phenix.eLBOW76, and were
manually fitted into difference maps (Fo-Fc) in Coot81, respectively. Structure refinement
for each crystal structure was performed in phenix.refine76 and the refinement and
structure statistics for each individual structure were summarized in Table 5.1 The
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simulated annealing (SA) ligand omit maps for in MDDEF-MVAPP, MDDEF-MVAPPAMPPCP-Mg2+

and

MDDEF-MVAPP-ADPBeF3-Mg2+

were

calculated

using

phenix.composite_omit_map76 and depicted using Pymol 61.

5.4

5.4.1

Results

Soaking experiments for obtaining ligand-bound crystal structures of
MDDEF
From our previous experiments, we know that MVAPP is the first substrate of

MDDEF, and that the binding of MVAPP appears to facilitate the binding of the second
substrate, MgATP. These results implied the first substrate binding may trigger structural
rearrangements in MDDEF. To test this, we would need the aid of crystal structures of
MDDEF without or with ligands to identify differences from those structures. The
crystallization condition for growing MDDEF-ATP crystals described in Chapter 2 was
not able to produce crystals of apoenzyme or ligand-bound structures of MDDEF. After
crystallization screening against six commercial trays (class I and II, and JCSG I, II, III
and IV from Qiagen) and condition optimization, we were able to obtain a stable
condition for growing apo-MDDEF crystals, and its space group was determined as
P21212, which is the same as the space group in MDDEF-ATP. Because of the high
concentration of (NH4)2SO4 at 1.6 M in the crystallization solution, MVAPP was not able
to bind to the enzyme using standard co-crystallization or soaking techniques. This
problem had also been discussed in the case of MDD from Homo sapiens69. In the
literature, co-crystallization for obtaining ligand-bound protein crystals is a frequently
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used option and had been used in growing tertiary complex crystals for MDD from S.
epidermidis59; however, different space groups and crystal packing may affect the
structural architecture at certain regions of interest. To avoid those potential artifacts, we
chose to use buffer exchange to wash away excess amounts of ammonium sulfate before
soaking experiments so that MVAPP can bind the active site of MDDEF. First we needed
to survey different buffer components that would keep the MDDEF crystals intact and
preserve their diffraction. From our previous findings, MDDEF-ATP crystals grew under
the condition containing 25 % PEG3350, implying that under this condition, MDDEF
protein crystals might not dissolve. Thus, we prepared soaking buffer containing 27%
PEG3350 and 50 mM sodium acetate, pH 4.6, and replaced the original buffer with this
soaking buffer. Although crystals cracked a little in the beginning of the buffer exchange
procedures, the “wounds” healed after a few minutes of equilibrium, and the bufferexchanged MDDEF crystals retained their original shape without dissolving. Tests of
diffraction from these crystals on the home source X-rays displayed resolution that
extended at least to 2.4 Å using I/ > 2 in the outer most shell as a criterion), and those
protein crystals maintained the same space group, P21212.
After three to four times of buffer exchange, MDDEF crystals were ready for the
soaking experiments. For preparing a MDDEF-MVAPP crystal, 0.12 l of 2 mM of
MVAPP in the soaking buffer were added into a 2-l drop containing a MDDEF crystal. It
was noticed that more than 0.15 l of MVAPP caused severe crystal cracking and
produced multiple crystals by breaking up one crystal. In order to cryo-protect these
crystals, we tried to add cryo-protectant directly into the top well containing MDDEF
crystals; however, this method caused severe crystal cracking.
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Our final procedure for cryo-protecting the buffer-exchanged MDDEF crystals
(without or with ligand soaking) was to add 50 l of the dehydration buffer into the
bottom well of the hanging drop chamber to condense the top well solution. After one
day of equilibrium, the solution surrounding a MDDEF crystal would have cryo-protection
so that no ice was formed in the crystal after flash-freezing the crystal in liquid nitrogen.
For preparing MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPP-ADPBeF3-Mg2+
crystals, one more step of ligand soaking was performed after the initial MDDEF-MVAPP
soaking experiment was done. Using these techniques, we have obtained MDDEF crystal
structures in an apo-form or in complex with ligands (MDDEF-SO42-, MDDEF-MVAPP,
MDDEF-MVAPP-AMPPCP-Mg2+,

MDDEF-MVAPP-ADPBeF3-Mg2+,

and

MDDEF-

MVAPP-ADP-SO42--Co2+). The data and refinement statistics are summarized in Table
5.1
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Table 5.1 Data collection and refinement statistics

Data collection*
Space group
Cell dimensions
a, b, c (Å)
 ()
Resolution (Å)
Rmeas (%)
I / I
Completeness (%)
Redundancy
CC1/2 (%)
CC* (%)

MDDEF–SO42-

MDDEF–MVAPP

MDDEF–MVAPP–
AMPPCP–Mg2+

P21212

P21212

P21212

82.4, 97.9, 45.7
90.0, 90.0, 90.0
33.4–1.8 (1.84–1.79)
6.6 (54.3)
32.3 (3.1)
99.2 (100.0)
7.0 (6.9)
92.6
98.1

79.3, 97.5, 45.8
90.0, 90.0, 90.0
50.0–1.7 (1.76–1.70)
5.4 (47.4)
40.1 (4.1)
99.5 (100.0)
6.8 (6.8)
93.1
98.2

80.0, 97.0, 46.0
90.0, 90.0, 90.0
30.0–2.1 (2.12–2.05)
4.6 (57.6)
38.6 (2.5)
96.6 (98.5)
5.1 (4.9)
84.6
95.7

Refinement
Resolution (Å)
33.4 – 1.8
30.8 – 1.7
25.6 – 2.1
No. reflections in
32861/1719
37860/1929
20979/1078
test/free R
Rwork / Rfree
19.7 / 22.6
16.4 / 18.9
18.1 / 21.4
Estimated
0.17
0.14
0.21
coordinate error (Å)
No. atoms
Protein
2607
2492
2528
Ligand/ion
10
18
50
Water
180
371
145
B-factors
Protein
20.7
12.9
30.9
Ligand/ion
26.5
8.23
35.4
Water
25.4
24.1
32.9
R.m.s. deviations
Bond lengths (Å)
0.006
0.008
0.007
0.93
0.92
0.80
Bond angles ()
Ramachandran Plot
Most Favored (%)
98.98
99.05
98.46
Allowed (%)
1.02
0.95
1.54
Outliers (%)
0
0
0
*Structure determined from one crystal.
*Values in parentheses are for highest-resolution shell.
*Each single crystal was placed in the soaking buffer containing 26 % PEG3350, 5 mM MgCl2, 50 mM
sodium acetate, pH 4.6.
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Table 5.1 Data collection and refinement statistics-continued

Data collection*
Space group
Cell dimensions
a, b, c (Å)
 ()
Resolution (Å)
Rmeas (%)
I / I
Completeness (%)
Redundancy
CC1/2 (%)
CC* (%)

MDDEF–MVAPP–
ADPBeF3–Mg2+

MDDEF–MVAPP–
ADP–SO42-–Co2+

P21212

P21212

79.8, 98.8, 45.7
90.0, 90.0, 90.0
25.0–2.4 (2.43– 2.35)
6.6 (81.5)
27.9 (2.1)
100.0 (100.0)
6.6 (6.3)
70.8
91.0

80.0, 98.1, 45.9
90.0, 90.0, 90.0
50.0–2.0 (2.02–1.95)
5.9 (52.9)
37.8 (3.5)
99.2 (100.0)
6.8 (6.7)
91.7
97.8

Refinement
Resolution (Å)
23.6 – 2.34
31.0 – 1.95
No. reflections in
14216/759
25189/1291
test/free R
Rwork / Rfree
18.9 / 22.5
19.3 / 21.7
Estimated coordinate
0.28
0.18
error (Å)
No. atoms
Protein
2539
2528
Ligand/ion
51
52
Water
105
219
B-factors
Protein
33.8
22.9
Ligand/ion
27.4
18.1
Water
32.1
28.21
R.m.s. deviations
Bond lengths (Å)
0.002
0.012
0.523
0.978
Bond angles ()
Ramachandran Plot
Most Favored (%)
97.85
97.85
Allowed (%)
2.15
2.15
Outliers (%)
0
0
*Structure determined from one crystal.
*Values in parentheses are for highest-resolution shell.
*Each single crystal was placed in the soaking buffer containing 26 % PEG3350, 5
mM MgCl2, 50 mM sodium acetate, pH 4.6.
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We have determined crystal structures of unbound and ligand-bound forms of
MDDEF. In the apo form of MDDEF, two regions, the phosphate binding loop (97-104)
and the 10-4 loop (183-190) cannot be determined due to poor electron density maps
in these regions. After soaking protein crystals with MVAPP, we determined the overall
structure of MDDEF-MVAPP (Fig. 5.1a), and surprisingly, we could determine the
conformation of the 10-4 loop (Fig. 5.1a, black line) and the MVAPP molecule in the
active site (Fig. 5.1b) based on the electron density maps. The binding pose of MVAPP in
our structure was similar to what was found in the case of MDDSE in complex with
FMVAPP and ATPS59. To show the binding of the second substrate, we prepared crystals
of MDDEF soaked with MVAPP and AMPPCP. In this structure, we can determine both
the 10-4 loop (Fig. 5.1c, black line) and the phosphate binding loop (Fig. 5.1c, red
line) based on the electron density maps in these regions, and also observe the electron
density of AMPPCP in the ATP binding pocket (Fig. 5.1d). In this structure, the 10-4
loop and the phosphate binding loop do not interact with ligands in the active site, and the
overall structure remained in an opened conformation. Finally, we prepared crystals of
MDDEF soaked with MVAPP and ADPBeF3 as a model mimicking a pre-phosphoryl
transfer state and determined this tertiary MDDEF crystal structure. In this structure, we
can determine the 10-4 loop (Fig. 5.1e, black line), the phosphate binding loop (Fig.
5.1e, red line), and ligands in the active site (Fig 5.1f). Intriguingly, only in this complex
do these two loops bend toward the active site. For this transition state intermediate
model complex, the overall structure was in a closed conformation.
In the structure with two bound substrates/analogues (MDDEF-MVAPPAMPPCP-Mg2+), in addition to the electron density for MVAPP and AMPPCP, we
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observed extra density between these two ligands. Since five oxygen atoms (one from
MVAPP, three from AMPPCP and one from -OH of Ser106) were found to be
surrounding the extra density within 2.8 Å, we hypothesized that this extra density
belongs to a magnesium ion. In the structure of MDDEF-MVAPP-ADPBeF3-Mg2+, we
also observed two extra densities in the active site besides MVAPP and ADPBeF3. One
surrounded by six oxygen atoms (one from MVAPP, two from ADPBeF3, one from the OH of Ser106 and one from water) was found to be at a position similar to the extra
density in MDDEF-MVAPP-AMPPCP-Mg2+, and another one was coordinated by five
oxygen atoms (three from water and two from MVAPP) and one fluorine atom from
BeF3-. This then suggested that these two extra electron density spheres were from two
magnesium ions.
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Figure 5.1 Structural models of bound forms of MDDEF. (a) A cartoon model of the
crystal structure of MDDEF-MVAPP with the MVAPP ligand shown as stick model.
(b)The SA-ligand omit map (3) of MVAPP in MDDEF-MVAPP is depicted. Residues
involved in substrate binding and the MVAPP model are shown in stick. (c) A cartoon
model of the crystal structure of MDDEF-MVAPP-AMPPCP-Mg2+ with the MVAPP and
AMPPCP ligands shown in stick model. (d) The SA-omit map (2.5) of ligands (MVAPP,
AMPPCP and Mg2+) in MDDEF-MVAPP-AMPPCP-Mg2+ is depicted; S106 involved in
metal chelating is shown in stick and one Mg2+ ion in green sphere. (e) A cartoon model
of the crystal structure of MDDEF-MVAPP-ADPBeF3-Mg2+ and the ligands shown in
stick and sphere. (f) The SA-omit map (2.5) of ligands (MVAPP, ADP, BeF3- and two
Mg2+ ions) in MDDEF-MVAPP-AMPPCP- Mg2+ is depicted; S106 and 3 water molecules
(in red sphere) involved in metal chelating are indicated; the catalytic residue, D282, is
shown in stick.
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5.4.2

Cobalt replacement in enzymatic and crystallographic studies reveal two
metal binding sites during MDDEF enzyme catalysis
In the active site of MDDEF-MVAPP-ADPBeF3-Mg2+, the two spherical densities

between MVAPP and ADPBeF3 were suggested to belong to magnesium based on the
octahedral coordination patterns. In the literature, cobalt has been shown to be an
alternative metal for MDDEF catalysis94. Cobalt can absorb the CuK X-ray radiation
available on a home source to produce detectable anomalous signals95. To confirm that
MDDEF utilizes cobalt for the reaction, we measured the enzymatic activity and obtained
the kinetic parameters (Vmax = 9.5 ± 0.3 mol/min/mg, KmMgATP = 188 ± 13 M, KmMVAPP
= 39.3 ± 4.0 M) under the condition with cobalt replacement (Fig. 5.2a and b). With
cobalt replacing magnesium, the value of Vmax was determined to be about 70%
compared with the Vmax value under the normal condition with magnesium. This was
similar to the result in the previous study94. Although cobalt can reduce the enzymatic
activity of pyruvate kinase in the coupled reaction assay, this assay can measure the
reaction velocity up to 85.4 ± 2.8 mol/min/mg (Fig. 5.2c) under the cobalt condition,
and that was fulfilled for reporting the MDDEF enzymatic activity under this condition.
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Figure 5.2 Kinetic study of MDDEF with two substrates under the condition with
Co2+. (a) Enzymatic reactions were performed at varying concentrations of MgATP (50,
100, 200, 400, 600, 800 and 1000 M) and a saturating concentration of MVAPP (300
M). Kinetics data were fitted into the Henri & Michaelis & Menten equation (v =
Vmax[S]/(Km + [S])). KmMgATP was 188 ± 13 M and Vmax is 9.5 ± 0.3 mol/min/mg (b)
Enzymatic reactions were performed at varying concentrations of MVAPP (10, 15, 25,
50, 100, 200 and 300 M) and a saturating concentration of MgATP (1000 M) and the
KmMVAPP value was 39.3 ± 4.0 M. (c) The values of capacities of enzyme-couple
reactions with the addition of either cobalt (10 mM) or magnesium (10 mM) were
determined at fixed concentrations of ADP (400 M), phosphoenolpyruvate (400 M)
and NADH (400 M). The assay under the cobalt condition can measure the rate of an
enzymatic reaction up to 85.4 ± 2.8 mol/min/mg, and the assay under the magnesium
condition can measure the rate of an enzymatic reaction up to 256.0 ± 5.6 mol/min/mg.
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Since we knew cobalt can be an alternative ligand for the reaction, we assumed
that cobalt could bind to the metal binding site(s) to perform its function. To test if there
are metal-binding sites in the closed form of MDDEF in complex with ligands, we
replaced magnesium with cobalt during the soaking process. We have obtained data sets
of MDDEF in complex with MVAPP, ADP, sulfate and cobalt (MDDEF-MVAPP-ADPSO42--Co2+) from synchrotron and home-source radiation. All the data sets were
processed in HKL2000 and structure refinement done in phenix.refine76. From the
synchrotron data, we obtained a 1.95Å-resolution structure and a SA-ligand-omit map as
depicted in Figure 5.3a. From the electron density map, we could observe two extra
spheres of electron density in the active site. At the home source, we collected a 360° data
set (1° oscillation per frame) and used the structure model derived from the synchrotron
data to generate the anomalous difference map (Fig. 5.3b) calculated from the F+/Fseparated data set. In the anomalous difference map, we could detect two strong
anomalous signals which are from cobalt, suggesting there are two metal binding sites,
and this was in agreement with the observation in MDDEF-MVAPP-ADPBeF3-Mg2+ (Fig.
5.1f).
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Figure 5.3 Ligand architectures in the crystal structure of MDDEF-MVAPP-ADPSO42--Co2+. (a) The refined structure was calculated from the 1.95Å synchrotron data set.
The SA-omit map (3) of ligands (MVAPP, ADP, SO42- and Co2+) is depicted in mesh
and ligands in stick and sphere and water in red sphere. (b) The phases from the refined
structure were used with the 2.34Å home-source data set. The anomalous difference map
(5) was depicted in mesh and ligands in stick and sphere.
5.4.3

Structural comparison provides insight into a detailed substrate binding
mechanism of MDDEF
The superimposition of these four structures revealed the dynamics of the

phosphate binding loop and the 10-4 loop upon substrate/ligand binding (Fig. 5.4). In
the closed conformation of MDDEF, two loops were found to bend to the active site to
interact with ligands. In MDDEF-MVAPP-AMPPCP-Mg2+, two loops were far from the
active site and their conformations were found to be different from those in MDDEFMVAPP-ADPBeF3-Mg2+ (9.5 Å difference in the 10-4 loops and 11.1 Å difference in
the phosphate binding loops in the open and closed forms of MDDEF) (Fig. 5.4).
We obtained open and closed structures of MDDEF with ligands, and the next step
would be to confirm these represent the initial binding or intermediate conformation right
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before enzyme catalysis. In the literature, the MDD family of proteins belongs to the
GHMP kinase family (galactokinases, homoserine kinases, mevalonate kinases and
phosphomevalonate kinases) sharing a common 3D structure fold. MDD has been
identified to trigger ATP-dependent decarboxylation of MVAPP in a mechanism where
the -phosphoryl group of ATP has been suggested to transfer to the 3’-OH group of
MVAPP before decarboxylation, meaning the -phosphoryl group of ATP would have to
be close to the 3’-OH group of MVAPP before catalysis.
By measuring the distances in these two complexes, we determined the distance
between the 3’ oxygen atom of MVAPP and the -phosphorous atom of AMPPCP to be
6.1 Å (Fig. 5.1d), and the distance between the 3’ oxygen atom of MVAPP and the
beryllium of ADPBeF3 to be 3.5 Å (Fig. 5.1f), respectively. The distance measurement
described above allows us to confirm that the closed form of MDDEF (the model from our
crystal structure of MDDEF-MVAPP-ADPBeF3-Mg2+) would be a conformation right
before MDDEF enzyme catalysis and the open conformation of MDDEF (the model from
our crystal structure of MDDEF-MVAPP-AMPPCP-Mg2+) would be an intermediate state
in which the second substrate loosely attaches onto the MDDEF protein, implied by a
large Ki value of AMPPCP in the previous kinetic study of MDD from chicken72 and our
preliminary enzymatic study (data not shown).
We suggest that our four crystal structures, MDDEF-SO42+, MDDEF-MVAPP,
MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPP-ADPBeF3-Mg2+, represent an apo
form, a first-substrate bound structure, a two-substrate bound structure in an opened
conformation and a two-substrate transition state intermediate in a closed conformation,
respectively. We analyzed the interactions between MDDEF and its ligands, shown as
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protein-ligand interaction profiles summarized in Table 5.2 From these interaction
profiles, we were intrigued to observe changes in the interaction patterns from those
structures. Most of the residues were found to be relatively stationary, forming stable
contacts with ligands; however, we identified some residues that interact with ligands
differently in the three bound forms of MDDEF (Gln68, Lys71, Ser106, Lys 187 and
Ser191). Those lead us to determine conformational changes in the active site upon
substrate binding.
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Figure 5.4 Overlay of unbound and bound forms of MDDEF structures (a) The
cartoon models of MDDEF–SO42- (white), MDDEF-MVAPP (yellow), MDDEF-MVAPPAMPPCP-Mg2+ (magenta) and MDDEF-MVAPP-ADPBeF3-Mg2+ (blue) are depicted and
covered with a transparent surface from MDDEF–SO42- (white). The greatest distance
between the 10-4 loops of MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPPADPBeF3-Mg2+ is 9.5 Å as indicated by a red arrow (measured between the C carbons
of E186 in both structures); the greatest distance between the phosphate binding loops of
MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPP-ADPBeF3-Mg2+ is determined to
be 11.1 Å and as indicated by a black arrow (measured between the C carbons of A101
in both structures). Three -helices, 1, 2 and 4, are also indicated (green text)
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Table 5.2The interaction profile a
Hydrogen bonds between donors and
acceptors
Atom of Ligand
(O01)
(O16)
(O18)
(O18)
(O17)
(O12)

MVAPP

(O01, O03)
(O13)
(O16,O18)

ATP,
AMPPCP
ADPBeF3

Mg
a

(O2', O3')
N6
N6
N7
O1B (Bridging
oxygen)
O3B
O3B
O2B
O1B (Bridging
oxygen)
O3G, BEF
(F01),
BEF (F03)
MG1

Atom of
MDDEF

Crystal structure
MDDEFATP

MDDEFMVAPP

Y17 (N)
2.89
K20 (NZ)
2.76
K71 (NZ)
2.8
S138 (OG)
2.9
G139 (N)
2.79
S140 (N)
3.03
R143
(NH1,
2.98, 2.8
NH2)
S191 (OG)
2.8
R192 (NE,
2.68, 2.95
NH2)
Q68 (O)
3.35 (O2')
S93 (OG)
3.26
N95 (OD1)
3.14
N95 (ND2)

MDDEF-MVAPP- MDDEF-MVAPPAMPPCP-Mg2+ ADPBeF3-Mg2+
2.96
2.6
2.65
2.7
2.89
3.13

2.95
2.71

3.02, 2.78

2.82, 2.86

2.48
2.77
2.98

2.84
2.69, 2.89

2.6, 2.84

3.01, 3.04
3.19
2.86

3.27
3

G102 (N)
S105 (N)
S105 (OG)
S106 (N)

3.07
3

3.36
3.13

K187 (NZ)
S191 (OG)
A283 (N)
S106 (OG)

2.96
2.35
3.01
2.66

2.37

2.99

2.7

3.21
1.95

The maximum distance cutoff between the hydrogen donor and the acceptor was set at 3.5 Å

Gln68 and Lys71 residues are located in Helix 1, Ser106 in Helix 2, and
Ser191 in Helix 4, and the gain or loss of interaction between these residues and
MDDEF implies that Helix 1, Helix 2 and Helix 4 might also change their positons in
different states of substrate binding and enzyme catalysis. By superimposing the crystal
structures described above, we could further track the differences in the helical center
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among these helices in these four structures. For Helix 1, the center of this helix moves
into four distinct positions in the four structures (1:apo MDDEF (MDDEF-SO42-); 2: firstsubstrate-bound MDDEF (MDDEF-MVAPP); 3: two-substrate-bound open conformation
of

MDDEF

(MDDEF-MVAPP-AMPPCP-Mg2+);

4:

two-substrate-bound

closed

conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg2+), Fig. 5.5a). From the
different positions of 1 in these four structures, we could imagine the helix movement
during the substrate binding event, and the movement was associated with the changes of
the interaction profiles between these two residues and ligands in these structures (Fig.
5.5b).
Ser106 in Helix 2 has also been identified to be involved in ligand binding in
this study; we observe that the center of 2 shifted in these four structures (Fig. 5.5c and
d). Helix 2 appears to move on the binding of MVAPP. From our structural observation
in MDDEF-MVAPP, the center of 2 (Fig. 5.5c, Position 2) moved to a position closer the
active site, if compared with the 2 position in the apo MDDEF (Fig. 5.5c, Position 1).
However, no direct contact has been found between this -helix and MVAPP within
possible hydrogen bonding distance (Hydrogen bond donor to acceptor < 3.5 Å).
Nonetheless, the binding of MVAPP could cause conformational changes in the active
site and prepare the active site environment for the subsequent steps of ligand binding
and catalysis. In the structures of MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPPADPBeF3-Mg2+, we did observe that the S106 residue composes a part of the metal
binding site (Fig. 5.5d). In MDDEF-MVAPP-AMPPCP-Mg2+, the distance between Mg2+
and -oxygen of S106 was determined to be 2.7 Å; in MDDEF-MVAPP-ADPBeF3-Mg2+,
the distance between Mg2+ and -oxygen of S106 was measured to be 1.95 Å (Table 5.2).
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Again, the distance difference of Mg2+-O in these two structures is also correlated and
consistent with the differences of 2 centers in these two structures (Fig. 5.5c, Position 3
and 4).
Ser191 is another conserved residue among the MDD family of proteins
suggested as a key residue for catalysis and MVAPP binding67. A S-to-A mutation at this
site has found to change the interactions between MVAPP and the key residues in the
active site (D283 and R144 in MDD from S. epidermidis)67. Ser191 is located at the Nterminus of Helix 4, and forms a hydrogen bond with the pyrophosphoryl group of
MVAPP in MDDEF-MVAPP (Fig. 5.5f, Table 5.2). Thus, Ser191 is suggested to be
involved in MVAPP binding, and correspondingly, the 4 helix center moves closer
towards the active site (Fig. 5.5e, Position 2) than that in the apo MDDEF (Fig. 5.5e,
Position 1). The centers of 4 in MDDEF-MVAPP-AMPPCP-Mg2+ (Fig. 5.5e, Position 3)
and MDDEF-MVAPP-ADPBeF3-Mg2+ (Fig. 5.5e, Position 4) do not differ from the one in
MDDEF-MVAPP. However, Ser191 in MDDEF-MVAPP-ADPBeF3-Mg2+ changes its
sidechain orientation, and new hydrogen bonding forms between Ser191 and Lys187, a
conserved residue from the 10-4 loop (Fig. 5.5f). Interestingly, Ser191 was found to be
involved in the interactions with MVAPP and the -phosphoryl group of AMPPCP in
MDDEF-MVAPP-AMPPCP-Mg2+, but the interactions no longer exist when all the
ligands are at their catalytically favored positions and the two loop close the entrance of
the active site in MDDEF-MVAPP-ADPBeF3-Mg2+.
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Figure 5.5 Movements of Helix 1, 2 and 4 and dynamic residues in the unbound
and bound forms of MDDEF. Four structures, MDDEF-SO42- (white), MDDEF-MVAPP
(yellow), MDDEF-MVAPP-AMPPCP-Mg2+ (magenta) and MDDEF-MVAPP-ADPBeF3Mg2+ (blue), are superimposed for the comparison of helices and residues. Ligands
(MVAPP, ADP, BeF3- and 2 Mg2+ ions) from MDDEF-MVAPP-ADPBeF3-Mg2+ are
represented in stick and sphere in (a), (b), (c), (d), (e) and (f). The centers of helices
(Helix 1, 2 and 4) are represented by red sticks assigned with serial numbers (1:
MDDEF-SO42-; 2: MDDEF-MVAPP; 3: MDDEF-MVAPP-AMPPCP-Mg2+; 4: MDDEFMVAPP-ADPBeF3-Mg2+). (a) The centers of 1 in these four structures are labeled with
numbers, respectively. (b) The interacting residues, Q68 and K71, in these four structures
are drawn in stick and colored corresponding to the cartoon models. (c) The centers of 2
are correspondingly labeled as described above. (d) The interacting residue, S106, in
these four structures is drawn in stick and colored correspondingly. (e) The centers of 4
are labeled in the same manner. (f) The interacting residue, S191, in these four structures
is drawn in stick and colored corresponding to the cartoon models. K187 in MDDEFMVAPP-ADPBeF3-Mg2+ was also shown in stick.
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5.5

5.5.1

Discussion

Structural comparison of MDDEF-MVAPP-ADP-SO42--Co2+ and MDDEFMVAPP-ADPBeF3-Mg2+
In the ATP-dependent decarboxylation reaction of MDD, divalent metal ions have

been suggested to be crucial for catalysis. Although under physiological conditions, Mg2+
is thought to be the essential ligand, other divalent ions were also examined to see if they
could function in the reaction (Mn2+, Co2+)94. In X-ray crystallography, metal ions can be
identified based on either anomalous signals produced at specific absorption wavelength,
the metal ion coordination patterns in the complexes, or the electron density. However,
magnesium is known to not produce detectable anomalous signals in most of cases, and
its electron density is not that different than a water molecule, so usually magnesium is
located based on the octahedral six-coordinate pattern formed by liganding atoms. In the
closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg2+), the electron
densities of MVAPP and ADPBeF3 were identified; however, two remaining spherical
densities suggested that they belong to two magnesium ions. We then did a soaking
experiment under the condition with 10 mM cobalt ions and collect X-ray diffractions on
the home-source X-ray equipment. Anomalous signals from the crystal structure of
MDDEF-MVAPP-ADP-SO42--Co2+ indicated two cobalt ions in the active site and thus
suggested that two spherical densities in MDDEF-MVAPP-ADPBeF3-Mg2+ belongs to
magnesium ions. We further compared these two structures by superimposition. The
overall structures of MDDEF-MVAPP-ADPBeF3-Mg2+ and MDDEF-MVAPP-ADP-SO42-Co2+ were nearly identical (r.m.s.d. = 0.17 Å) (Fig. 5.6a). The actives-site ligands were
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also well-superimposed; however, there is a significant difference between these two
structures in the metal binding site (Fig. 5.6b). This is most likely due to the different
ligands in the active site (SO42- or BeF3-), although the specific metal might contribute.

Figure 5.6 The structural comparison of MDDEF-MVAPP-ADP-SO42--Co2+ and
MDDEF-MVAPP-ADPBeF3-Mg2+. (a) The superimposition of the cartoon models of
MDDEF-MVAPP-ADP-SO42--Co2+ (orange) and MDDEF-MVAPP-ADPBeF3-Mg2+ (blue)
were shown in stereo. (b) The superimposition of ligands of two structures is shown in
stereo with residues and molecules labeled.

96
5.5.2

A conserved Ser106 residue in Helix 2 functions as an anchoring point for
metal binding
A conserved serine residue (Ser107 in MDDSE) was previously defined as an

anchoring point for the binding of -phosphoryl group of ATP in the case of MDD from
Staphylococcus epidermidis59,67 with a functional study that indicated the mutation on
this residue dramatically affects the enzymatic activity (Fig. 5.7a). In our study, this
conserved serine residue (Ser106) has been clearly identified to be involved in binding
the metal ion (Mg2+ in our case) (Fig. 5.7b) In addition, the -thiophosphate of ATPS
was sitting in the same site as one of the two metals (MG1) in our structure (MDDEFMVAPP-ADPBeF3-Mg2+)(Fig. 5.7c). In the MDDSE 2fo-fc (Fig. 5.8a) and fo-fc (Fig.
5.8b) maps of the tertiary structure of MDDSE (4DPT), there is some indication of a
problem in their interpretation of the ligand architecture and the role of the conserved
serine residue due to the negative peaks around the -thiophosphate of ATPS (Fig. 5.8b).
In their model, the distance between the -phosphorus of ATPS and the 3’-oxygen of
FMVAPP was measured to be 5.5Å (Fig. 5.8a and c), which is too long for a phosphoryl
transfer reaction to occur. In our crystal structure of MDDEF-MVAPP-ADPBeF3-Mg2+,
the distance between the beryllium of ADPBeF3 and the 3’-oxygen of MVAPP was
measured to be 3.5Å (Fig. 5.8b and c). These observations suggest that our structural
models better represent the closed form of MDD during enzyme catalysis.
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Figure 5.7 The structural models of MDD from Staphylococcus epidermidis (MDDSEFMVAPP-ATPS, PDB: 4DPT) and Enterococcus faecalis (MDDEF-MVAPPADPBeF3-Mg2+). (a) The ligands, FMVAPP and ATPS, in the active site of MDDSEFMVAPP-ATPS. The distance between the 3’-oxygen of MVAPP and the -phosphorus
of ATPS is 5.5 Å. Ser107 is indicated. (b) The ligands, MVAPP, ADPBeF3 and 2
magnesium ions (MG1 and MG2), in the active site of MDDEF-MVAPP-ADPBeF3-Mg2+.
The distance between the 3’-oxygen of MVAPP and the -phosphorus of ATPS is 3.5 Å.
(c) The stereo of the superimposition of the structural model from (a) and (b). The
conserved Asp residues in both structures (D283 in MDDSE-FMVAPP-ATPS and D282
in MDDEF-MVAPP-ADPBeF3-Mg2+) are also indicated and shown in stick.
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Figure 5.8 The 2Fo-Fc and Fo-Fc maps from the complex structure of MDD from
Staphylococcus epidermidis (MDDSE-FMVAPP-ATPS, PDB: 4DPT). (a) The
extracted 2fo-fc (1) electron density maps around active-site ligands are depicted in blue
mesh. (b) The extracted fo-fc (3) electron density maps around active-site ligands are
depicted in green mesh (positive peaks) and red mesh (negative peaks). (a) and (b) are
shown in stereo mode. S106 and D282 are conserved residues in MDDEF from the crystal
structure of MDDEF-MVAPP-ADPBeF3-Mg2+.
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5.5.3

New insight into a detailed enzyme mechanism of MDDEF
To imagine the physical steps of the MDDEF enzymatic reaction, here we propose

a substrate binding model (Fig. 5.9) with conformational changes. The binding of
MVAPP causes initial structural rearrangements, including the positioning of the 10-4
loop and three helices (1, 2 and 4) shifting positions. We believe that the movement
of 1 toward the active site create suitable binding site for ATP and make ATP binding
stronger. The binding of ATP would then stabilize the phosphate binding loop and also
bring one magnesium ion to the active site to neutralizing the negatively charged
environment produced by the pyro- and tri-phosphoryl moieties of both substrates.
Interestingly, AMPPCP in MDDEF-MVAPP-AMPPCP- Mg2+ binds the MDDEF-MVAPP
complex differently from ADPBeF3 in MDDEF-MVAPP-ADPBeF3-Mg2+ in the adenosine
(Fig. 5.10a) and the triphosphate-mimicking moieties (Fig. 5.10b), which are
corresponding to the interaction between ligands and the MDDEF enzyme (Table 5.2).
This outcome suggests that the --bridging oxygen of ATP would be a checkpoint during
in the substrate binding event because it serves as an anchoring point for the phosphate
binding loop to move toward the active site and form interactions with ATP. The second
magnesium ion appears to fit into the active site before the close of the active site
entrance for catalysis. Although the angles between helical centers in different structures
may vary due to the different alignment methods, we determined the interaction patterns
between active site ligands and the protein to confirm that the angular changes were
meaningful (Table 5.3).
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Figure 5.9 A proposed substrate binding model of MDDEF during enzymatic
reaction. Four structures (1-4) represent the four states during the enzymatic reaction 1:
an unbound form of the MDDEF protein. In this state, the phosphate binding loop and the
10-4 loop are dynamic. 2: a structure of MDDEF bound with its first substrate, MVAPP.
The binding of MVAPP triggers conformational changes and the 10-4 loop (yellow)
becomes ordered. 3: an open conformation of MDDEF in complex with MVAPP and ATP.
The binding of ATP stabilizes the phosphate binding loop (magenta, top). 4: a closed
conformation of MDDEF in complex with MVAPP and ATP after conformational
rearrangement from the opened conformation. In this state, the two loops swing and close
the active-site entrance, and catalysis is as following.
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Figure 5.10 Structure comparison of ligands in the active site of the crystal
structures of MDDEF-MVAPP-AMPPCP-Mg2+ and MDDEF-MVAPP-ADPBeF3Mg2+. Ligands and residues involved in the binding of ATP from MDDEF-MVAPPAMPPCP-Mg2+ are colored in black. Ligands and residues from MDDEF-MVAPPADPBeF3-Mg2+ are colored in blue. (a) The difference between the adenosine moieties of
AMPPCP and ADPBeF3 in these two structures. (b) The difference between the phosphate of AMPPCP and BeF3- of ADPBeF3 in these two structures.
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Table 5.3 Comparison of helix angles in the unbound and bound forms of MDDEF
Angle between helices in A
and B (°)

Crystal structure
A

B

1

2

4

MDDEF-SO42-

MDDEF-MVAPP

4.9

4.0

11.0

MDDEF-MVAPP

MDDEF-MVAPP-AMPPCP-Mg2+

0.9

1.8

0.6

MDDEF-MVAPP-AMPPCP-Mg2+ MDDEF-MVAPP-ADPBeF3-Mg2+

8.6

2.2

1.3

MDDEF-SO42-

4.9

7.2

11.1

MDDEF-MVAPP-ADPBeF3-Mg2+

* The angles were obtained using the Pymol script “AngleBetweenHelices” created by Thomas
Holder.

The conserved aspartate residue (D282 in MDDEF) has been recognized as a
catalytic residue for deprotonization of the 3’-OH group of MVAPP. It is believed that
the intermediate 3’-O--MVAPP would attack the -phosphoryl group of ATP to initiate the
phosphoryl transfer reaction, followed by the spontaneous dephosphorylation and
decarboxylation of the intermediate ligand 3’-phosphate-MVAPP. In the closed form of
MDDEF (MDDEF-MVAPP-ADPBeF3-Mg2+), we observed that the distance between the
phosphoryl donor (O of ADP) and the acceptor (3’-O of MVAPP) was measured to be
5.8 Å. In the literature, the Pauline bond order calculation has been frequently used for
determining either an associative or dissociative phosphoryl transfer mechanism in
protein kinases or phosphatases96. The Pauline bond order is calculated using Equation
5.1, where D(n) is the half distance between the phosphoryl donor and acceptor, D(1) is the
single bond distance (1.73 Å for the P-O bond) and n is the bonding order.

𝐷(𝑛) = 𝐷(1) − 0.6 × log(𝑛)
Equation 5.1
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By using this equation with the experimental 5.8 P-O distance (Fig. 5.11), n was
calculated to be 0.011, meaning that the phosphoryl transfer 1.1 % associative and 98.9%
dissociative. Coordinate uncertainty exists in a refined structure model, and there are
ways to estimate the coordinate uncertainty97. We used coordinate error for the estimation
since it also takes the diffraction-component precision index (DPI) and B-factor of each
atom into consideration98. If the coordinate error (0.28Å) in this structure is considered,
the bond order in the transition state of phosphoryl transfer would range from 0.280
(72.0% dissociative) to 0 (100.0% dissociative). This result suggested that if both the
phosphoryl donor and acceptor do not change their positons during the phosphoryl
transfer reaction, the reaction would likely be dissociative phosphoryl transfer. In the
closed structure, the ligands are found to be tightly packed in the active site; any
movement of MVAPP and/or ADP would cause severe steric clashes. Assuming no
substantial movement of the MVAPP molecule, we suggest that there would be a
dissociative phosphoryl transfer reaction taking place during the chemical steps of
MDDEF enzyme catalysis.
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Figure 5.11 The distance measurement between the in-line phosphoryl transfer
donor and acceptor. The distance between 3’-O of MVAPP (acceptor) and O of ADP
(donor) was measured to be 5.8 Å.
In the closed conformation, a dissociative phosphoryl transfer would occur and
produce a metaphosphate ion in the transition state of catalysis. The metaphosphate ion
would be escorted possibly by the metal ions and the Lys187 residue to the 3’-OH group
of MVAPP to form 3’-phosphate-MVAPP, followed by spontaneous dephosphorylation
and decarboxylation to produce IPP (Fig. 5.12).
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Figure 5.12 A proposed dissociative phosphoryl transfer mechanism of MDDEF
during the enzymatic reaction. 1: de-protonization of the 3’-OH group of MVAPP (red)
is done by D282. 2: dissociative phosphoryl transfer occurs and the metaphosphate
(blue) would be produced. 3: The metaphosphate would attach to the 3’-O- group (red) of
MVAPP. And 4: dephosphorylation and decarboxylation would occur to form products,
IPP, ADP, PO42- and CO2. K187 from the 10-4 loop and metal ions are involved in
neutralizing the negatively charged environment in the active site during catalysis. The
phosphate binding loop (gray shadow) was involved in the ATP binding in the close form
of conformation.
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The pKa value of the carboxyl group of Asp in solution is about 3.9, and the
soaking buffer contains 50 mM sodium acetate, pH 4.6. Using Equation 5.2, where [HA]
is the concentration of the protonated aspartate and [A-] is the concentration of
deprotonated aspartate, we could roughly estimate that the side chain of Asp282 is 20%
protonated.

pH = pKa − log

[HA]
[A- ]
Equation 5.2

The relative enzymatic activities of MDD from rates99 and chickens100 had been
determined under different pH conditions. In both cases, MDD enzymes showed a 50%
enzymatic activity at pH 4.6 compared relative to the enzymatic activity determined at
pH 7. At pH 4.6, ATP is mainly protonated to “HATP3-“84, and the dissociation constant
between Mg2+ and HATP3- is about 1.58 mM85. These might explain the pH effects on the
decrease of the MDD enzymatic activity. However, the active MDD enzymes under
acidic conditions (above pH 3) suggest the functional catalytic residues in the active site
and the accessible binding of true substrates. In our crystal structures, the Asp282 residue
could be partially protonated, but the majority of Asp282 in the crystal should be
functional for the deprotonation of the 3’-OH group of MVAPP. Although we assume that
the dissociative phosphoryl transfer might occur during the chemical steps of the
decarboxylation, we still need experimental approaches to elucidate the detailed
chemicals steps of the MDDEF decarboxylation the protein and a phosphoryl transfer
reaction mechanism.
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CHAPTER 6. THE DIMISHED ENZYME ACTIVITYOF THE K187A MUTANT
REVEALS THE IMPORTANCE OF THE CONSERVED LYSINE IN THE
ENZYME MECHANISM

6.1

Chapter Summary

In the closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg2+), we
observed that a conserved lysine (Lys187) forms hydrogen bonds with Ser191 and O of
ADPBeF3 in the active site. We then created a K187A mutant of MDDEF by site-direct
mutagenesis and determined the enzymatic activity of the K187A mutant. Intriguingly,
the K187A mutant showed a 300-fold decrease in the enzymatic activity if compared with
wild type MDDEF. This suggested that K187 is essential for the enzymatic reaction. To
test if this lysine is involved mainly in substrate binding, we performed ITC experiments
and the thermodynamic data showed that the mutation of lysine to alanine only affects the
binding affinity between ATPS and MDDEF-MVAPP about 2 fold, suggesting that this
residue would be mainly involved in catalysis. Our findings also implicated that the
conserved serine residue (S191 in MDDEF) may serve as an anchoring point for
positioning Lys187 during catalysis.

6.2

Introduction

Positively charged residues, such as lysine or arginine, have been shown to play
important roles in substrate binding or neutralizing the negatively charged active site in
kinases96,101. MDD is a member of GHMP kinase family of proteins (galactokinase,
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homoserine kinase, mevalonate kinase, phosphomevalonate kinase)59 and it triggers ATPdependent decarboxylation of MVAPP. In MDDEF, the conserved K71 (Arginine in
eukaryotes) and Arg144 are known to be responsible for the binding of MVAPP. From
our crystal structures, another conserved lysine residue (Lys187) has also been found to
be located in the active site when the protein binds its two substrates and ligands. This
implies that Lys187 may also play a pivotal role “transiently” during catalysis. Previously,
this conserved lysine was identified to be functional in the case of MDD from rats58;
however, this lysine has not yet been annotated as a key residue for catalysis or substrate
binding58. In the closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg2+), we
observed that Lys187 interacts with ADPBeF3 and Ser191 in the active site. This suggests
that this residue may assist the binding of ATP and/or facilitate enzyme catalysis. To test
that, we created the K187A mutant, determined its relative enzymatic activity versus the
wild type MDDEF and also measured the dissociation constants between the K187A
mutant and ligands under various conditions. These results will help us to identify the
role of Lys187 in the MDDEF enzymatic reaction.

6.3

6.3.1

Materials and Methods

Site-directed mutagenesis
The K187A mutant was created by side-direct mutagenesis. The sequence of the

forward primer from 5’ to 3’ is “CTTAATTAATGATGGCGAAGCAGATGTTT
CCAGCCGTGATG”, and the sequence of the reverse primer is “CATCACGGC
TGGAAACATCTGCTTCGCCATCATTAATTAAG”. The 50 l PCR solution contains
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the forward and reverse primers (1 M, respectively), dNTP (200 M of each), Phusion
HF buffer (1X), template DNA (0.1 l ~ 1 l), DMSO (2%), Phusion DNA polymerase
(one unit) and sterile water. The PCR program was set to be 1 cycle of denaturation (95℃,

one minute), 25 cycles of the 3-step reaction (1. Denaturation, 95℃, 30 seconds; 2.

Annealing, 62℃, 30 seconds; 3. Extension, 72℃, 5 minutes and 30 seconds), one cycle

of the final extension (72℃, 10 minutes) and overnight incubation at 4℃. After the PCR
procedure, the old template containing methylated DNA was then digested by Dpn1 (1 l)
for one-hour treatment at 37℃.

6.3.2

Sequence alignment and structural annotation
The sequences of MDD proteins from organisms (Enterococcus faecalis;

Enterococcus

faecium;

Staphylococcus

epidermidis;

Staphylococcus

aureus;

Streptococcus pyogenes; Listeria monocytogenes; Homo sapiens; Trypanosoma brucei;
Mus. musculus; Xenopus tropicalis; Bos taurus; Arabidopsis thaliana) were aligned using
EBI Clustalw Omega82. The secondary structure elements were drawn using
ESPript3.0102 based on the structural model of MDDEF in complex with MVAPP, ADP,
cobalt and sulfate (MDDEF-MVAPP-ADP-SO42--Co2+) in this study.
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6.3.3

Enzymatic activity of wild type MDDEF and the K187A mutant
The enzymatic activity of MDDEF and the K187A mutant was determined using an

ATP/NADH enzyme-coupled assay, respectively. Each reaction was performed at 30℃
under the buffer condition (100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl 2, 0.2
mM NADH, 0.4 mM phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate
dehydrogenase, and 100 nM MDDEF59). Initial velocity of each reaction was determined
at a concentration of ATP (800 M) and MVAPP (200M). Relative enzyme activity of
the K187A mutant was calculated by dividing the average enzymatic velocity of the
K187A mutant by the average enzymatic velocity of wild type MDDEF.

6.3.4

Isothermal titration calorimetry (ITC) experiments
The preparation of the TEV-treated K187A mutant proteins was the same as the

preparation of TEV-treated wild type MDDEF described previously. The protein solution
was dialyzed against the same buffer used in the enzymatic reaction and the final protein
conce
solutions (260 l) were titrated with ligands (MVAPP, ATP and ATPS) which were also
prepared in the same buffer and the concentration of each titrant was optimized in
different experiments. The temperature for ITC experiments was set at 25 ℃. Each
experimental profile composed of the addition of an initial aliquot of 0.4 l, followed by
22 aliquots of 1.8 l of the substrate or ligand solution. The time interval between two
consecutive injections was 180s. The experimental designs were done using the
MICROCAL ORIGIN 7.0 software package. The data were further processed with NITPIC 92
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and analyzed using the one-site model in SEDPHAT93. Figures were generated using
GUSSI.

6.4

Results

To investigate the role the conserved lysine (K187 in MDDEF) in the enzymatic
reaction, we performed site-directed mutagenesis to create the K187A mutant of MDDEF
and the PCR result was shown in Figure 6.1. The protein expression and purification
procedures were the same as used in our previous study of wild type MDDEF. French
press was employed to break down the cells and the supernatant containing soluble
proteins was collected and pumped through a Ni-NTA column. The His-tagged K187A
mutant proteins were trapped on a Ni-NTA column and eluted by increasing
concentrations of imidazole in buffer B described in the previous chapter, and the
purification profile, SDS-PAGE analysis and TEV-treatment results were shown in
Figure 6.2. We have successfully purified the K187A mutant form of MDDEF and those
proteins were used for the determination of the relative enzymatic activity and the Kd
values of ligands in our study.
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3 kb

(125 ng)

Figure 6.1 The PCR product of K187A mutant. The K187A mutant was created by
side-direct mutagenesis. The sequence of the forward primer from 5’ to 3’ is
“CTTAATTAATGATGGCGAAGCAGATGTTTCCAGCCGTGATG”; the sequence of
the reverse primer is “CATCACGGCTGGAAACATCTGCTTCGCCATCATTAATTAAG”. The DNA latter was loaded in the first line and the 3-kb was indicated. The plasmid
of MDDEF was loaded in the second line for estimating the size of the PCR product of the
K187A-mutant plasmid.
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Figure 6.2 Protein purification of K187A mutant. (a) The purification profile of the
K187A mutant. Fractions from 8 through 17 were polled for further dialysis. (b) Cell
pellets before induction (w/o induction), after IPTG induction (IPTG induction), pellet
(Pellet) and supernatant (supernatant) after French press, protein solution after the Ni2+
column (flow through) and protein eluted fractions (8, 10, 12, 14, 16 and 17) were
examined by SDS-PAGE after protein purification. (c) Protein solution of the K187A
mutant were checked by SDS-PAGE before and after TEV-protease-treatment.
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From our previous enzymatic study, we determined the Kdmvapp value to be about
40 M, and the KdATP value was about 160 M. We then performed enzymatic reactions
for both wild type MDDEF and the K187A mutant at about saturated concentrations of
both substrates in the reaction buffer (MVAPP = 200 M, ATP = 800 M). The enzymatic
activity of the K187A mutant was calculated and its relative enzymatic activity was
expressed as a percentage of wild type MDDEF enzymatic activity. A value of 0.35%
activity relative to the value of wild type MDDEF indicated that this conserved lysine
residue (Lys187) is essential for the enzymatic reaction (Fig. 6.3). Although we did not
determine the KmMVAPP and KmMgATP values for the K187A mutant, we performed ITC
experiments to determine the actual Kd values of MVAPP and ATPS to infer that if the

Relative enzyme activity (%)

lysine affects substrate binding.

100

50

0.35
0

MDDEF

K187A
mutant

Figure 6.3 Relative enzyme activity of the K187A mutant compared to MDDEF. The
enzyme activities of MDDEF and K187A mutant of MDDEF had been determined at
saturating concentrations of two substrates (MVAPP = 200 M; MgATP = 800 M) and
normalized by the means of wild-type MDD enzyme activity. The means and the standard
deviation were derived from each triplicate.
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All the ITC experiments for the K187A mutant were performed (Fig. 6.4a to d)
and the experimental parameters were basically similar to what we used for determining
Kd values in the cases of wild type MDDEF. All the derived thermodynamic parameters
are listed in Table 6.1. First, the KdMVAPP value was determined as 8.7 ± 5.4 M (Table
6.1a), which is about a two-fold decrease compared with the value of KdMVAPP in wild
type MDDEF (20.4 ± 9.3 M, Table 4.1a). A two-fold difference in binding affinity (1/Kd)
may not be considered significant in general. The KdATP value was 495 ± 91 M (Table
6.1b), which is about 1.5-fold greater than KdATP in MDDEF (288 ± 36 M, Table 4.1b).
And the KdATPS value was 182 ± 36 M (Table 6.1c), which is about equal to the value of
KdATPS in MDDEF (215 ± 8 M, Table 4.1c). In the presence of excessive MVAPP in the
K197A protein solution (100 M of K187A + 1 mM of MVAPP), KdATPS was determined
as 58.2 ± 13.2 M (Table 6.1d), and under the same condition in the case of wild type
MDDEF, the difference in Kd is about two-fold (25.4 ± 5.5 M, Table 4.1d). However, the
KdATPS is 4-fold smaller than KdATPS of 182 M determined under the condition without
MVAPP (Table 6.1c). These results suggest that the prerequisite binding of MVAPP to the
K187A mutant can also enhance the binding of ATPS. Although the K-to-A mutation
does not cause significant changes in substrate binding ability, this mutation dramatically
affect the enzymatic activity by 300 folds (Fig. 6.3), which indicates that this Lys187 may
serve as a key residue mainly in catalysis.
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Figure 6.4 The original titration curve of ITC experiments. (a) The K187A mutant
(100 M) was titrated with MVAPP (1 or 2 mM). (b) The K187A mutant (100 M) was
titrated with ATP (3 mM). (c) The K187A mutant (100 M) was titrated with ATPS (3
mM). (d) The K187A mutant (100 M) was pre-incubated with MVAPP (1 mM) and then
titrated with ATPS (2 mM). The thermodynamic parameters of each experiment are
listed in Table 6.1.
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Table 6.1 Thermodynamic parameters*

a
b

Species

Substrate

K187A
(100 M)

MVAPP
(1 mM
or 2 mM)
ATP
(3 mM)
ATPγS
(3 mM)
ATPγS
(2 mM)

Kd
(µM)
8.7 ± 5.4

K187A
495 ± 91
(100 M)
c
K187A
182 ± 36
(100 M)
d
K187A
58.2 ± 13.2
(100 M)+
MVAPP
(1 mM)
*Titration experiments were done at 25℃.

ΔG**
(kcal/mol)
-7.1 ± 0.3

ΔH
(kcal/mol)
-0.6 ± 0.1

-4.5 ± 0.1

-4.4 ± 1.5

0.1 ± 0.9

0.4 ± 2.9

-5.1 ± 0.1

-6.3 ±0.4

-1.2 ± 0.2

-4.0 ± 0.8

-5.8 ± 0.1

-2.1 ± 0.4

3.7 ± 0.2

12.4 ± 0.8

𝑚

** The mean of ΔG () is derived from the equation: μ = −RTln (

√1+

of ΔG () is calculated from the equation: σ = √ln (1 +

𝑣
𝑚2

𝑣
𝑚2

TΔS#
ΔS
(kcal/mol) (cal/mol*K )
6.5 ± 0.2
21.9 ± 0.7

) and the standard deviation

), where m is the mean of the association

constant (Ka) and v is the variance of Ka derived from each ITC experiment.
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2)
and the standard deviation () of TS is derived from the equation: 𝜎1−2 = √
the standard deviation of G and 2 is the standard deviation of H.

𝜎1 2
𝑛

+

𝜎2 2
𝑛

, where 1 is
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6.5

Discussion

The results of multiple sequence alignment and crystal structures show that there
are several lysine and arginine residues in the active site, and many of them have been
annotated for the binding of substrates (Fig. 6.5). From our enzymatic and
thermodynamic studies, the conserved Lys187 in the un-conserved 10-4 loop is
suggested to be involved mainly in the chemical steps of catalysis. In our crystal
structures, we knew that this 10-4 loop swings to close the substrate entrance when all
the ligands are bound in the active site. This suggests that this conserved Lys187 could be
transiently involved in the reaction during catalysis. Interestingly, the Ser191 residue also
rotated its sidechain to interact with Lys187 in the closed conformation of MDDEF (Fig.
5.5f), which implies that this conserved serine may also play roles during the enzymatic
reaction. This serine has been reported to be important for the enzymatic activity, yet its
role has not been annotated. From our structural observations, this serine may also serve
as a transiently anchoring point for accommodating the Lys187 residue for catalysis.
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Figure 6.5 Extracted multiple sequence alignment. Sequences corresponding to the
organisms (E. faecalis; E. faecium; S.epidermidis; S. aureus; S. pyogenes; L.
monocytogenes; H. sapiens; T. brucei; M. musculus; X. tropicalis; B. taurus; A. thaliana)
were aligned using Clustal Omega 82 and the extracted figure containing structural
elements and the sequence alignment was generated using ESPript3.0 102. Identical
residues and homologous residues are boxed and shaded in black and white based on
BLOSUM matrix (BLOSUM62). Residues characterized to be functionally important
from the literature among MDD proteins are marked with solid triangles58,59,67; residues
involved in substrate interaction are marked with empty stars; the phosphate binding loop
and the 10-4 loop are indicated with curved ribbons in black and grey, respectively.
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CHAPTER 7. HIGH-THROUGHPUT SCREENING FOR MDDEF SPECIFIC
DRUG DISCOVERY

7.1

Chapter Summary

The human mevalonate diphosphate decarboxylase is a member of the MDD
family of proteins and performs the same decarboxylation reaction of MVAPP as MDDEF
to produce isopentenyl diphosphate. The active site environment of MDD proteins is
highly conserved, and that makes specific drug development against MDDEF challenging.
In addition to performing high-throughput screening (HTS) for selecting MDDEF potent
inhibitors, we will need human MDD as a negative control for achieving compound
selectivity against MDDEF. We performed auto-induction to successfully produced
functional human MDD and purified proteins to homogeneity using Ni2+-NTA affinity
chromatography. Meanwhile, we established a high-throughput screening assay method
for identifying potential inhibitors against MDDEF. Although we had 14 compounds
identified from HTS, the follow-up examination indicated that the leads from HTS are
false positive ones. We will focus on improving HTS assay methods for the future
MDDEF drug discovery.

7.2

Introduction

The MDD family of proteins acts on MVAPP and produce IPP, and the active site
environment is highly conserved, which has been observed by multiple sequence
alignment (Fig. 6.5). This indicates that even the primary sequences of human MDD and
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MDDEF share < 30% sequence identity, the overall structure of MDD proteins and their
key residues in the active site for substrate binding and catalysis are well conserved69. In
order to identify selective inhibitors against MDDEF instead of human MDD, we will
need human MDD and perform assays to exclude compounds which have inhibitory
ability against human MDD proteins. In the literature, human MDD has been successfully
produced and tested enzymatically69; however, in our preliminary results, we would not
be able to produce functional proteins using the same reported protocol, so we will need
to modify the human-MDD purification strategy. In addition, the coupled enzyme
reaction (pyruvate kinase/lactate dehydrogenase) method has been used in highthroughput screening (HTS) for identifying potential inhibitors against the mevalonate
diphosphate decarboxylase from Streptococcus pneumonia (MDDSP). Previously we have
established an in vitro assay method for studying MDDEF enzyme kinetics. This can then
be modified for HTS against MDDEF.

7.3

7.3.1

Materials and Methods

Cloning, expression and purification of the recombinant form of Human
MDD
The plasmid (pET-23d) encoding the hMDD gene fragment was purchased from

Addgene69 (pET-23d-hMDD). The sequence was confirmed by the low-throughput
sequencing center at Purdue. E. coli BL21 (DE3) cells were transformed with pET-23dhMDD. The transformed cells were cultured in the auto-induction medium (6 g/L
Na2HPO4, 3 g/L KH2PO4, 20 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl, pH 7.2)
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supplemented with Ampicillin (100 mg/ml) at 37 ℃ to an A600nm of 0.3. Auto-induction
solution (10 ml of 60% glycerol; 5 ml of 10% glucose; 25 ml of 8% lactose) was added to
the bacterial culture to induce protein expression at 25 ℃ for 20 hours. Cells were
harvested by centrifugation at 8000 rpm for 10 minutes, re-suspended in binding buffer
(50 mM of sodium phosphate at pH 7.4, 300 mM of NaCl, and 10 mM of imidazole), and
lysed to homogeneity by French Press at 1500 psi. After centrifugation at 15000 rpm for
15 minutes, His-tagged hMDD proteins were soluble in supernatant and then trapped on a
Ni2+-NTA column. The proteins were eluted from the column with the increasing
gradient of elution buffer (50 mM sodium phosphate, pH 7.4, 300 mM NaCl, and 300
mM imidazole) from 0% to 100%. Eluted fractions of hMDD were collected and desalted
in dialysis buffer (25 mM Tris-HCl, pH 8, 100 mM NaCl, and 10 mM MgSO4). The
protein solution was concentrated to 1.6 mg/ml by ultrafiltration and stored at -20 ℃.

7.3.2

Comparison of enzymatic activity of human MDD and wild type MDDEF
Enzymatic activity of MDDEF and human MDD was determined using an

ATP/NADH enzyme-coupled assay, respectively. Each reaction was performed at 30℃
under the buffer condition (100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 0.2
mM NADH, 0.4 mM phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate
dehydrogenase, and 100 nM MDDEF)59. Initial velocity of each reaction was determined
at a concentration of ATP (1000 M) and MVAPP (300 M). Relative enzymatic activity
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of human MDD was calculated by dividing the enzymatic velocity of human MDD by the
enzymatic velocity of wild type MDDEF.

7.3.3

High-throughput screening for hit selection against MDDEF
An ATP/NADH enzyme-coupled assay was used for determining enzymatic

activity of MDDEF in high-throughput screening using the LOPAC library (Sigma). Two
kinds of master solutions were prepared separately. Master Solution A (MSA) contains
100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 4 units of pyruvate kinase, 4
units of lactate dehydrogenase, 100 M MVAPP, and 20 nM MDDEF. Master Solution B
(MSB) contains 100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 2 mM NADH, 2
mM phosphoenolpyruvate (PEP), 1 mM ATP. The assay was performed in a 1536-well
plate format. 4 l of MSA was dispensed into each well, followed by the addition of 0.02
l of each compound from the LOPAC library using the HTS facility in Bindley at
Purdue. 1 l of MSB was then dispensed into each well, and MDDEF enzymatic activity
of each well was determined by monitoring A340nm decrease. The Z-score value was
calculated to evaluate the assay quality and each reaction was monitored at room
temperature for 30 minutes with 30-second intervals.

7.3.4

Follow-up assays for hit selection against MDDEF
IC50 values of potential hits from HTS were further determined. To determine

IC50 values, a 1/2 serial dilution for each compound (0, 1.25, 2.5, 5, 10, 20, 40 and 80 M)
was made with MSA and prepared in a 384-well plate. The above solution was then
transferred to a 1536-well plate and the following procedures were the same as HTS
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described above. Percent inhibition of MDDEF enzymatic activity was calculated and the
IC50 value of each compound was determined by fitting the inhibition data to a
Michaelis–Menten kinetics model using GraphPad Prism 6.

7.4

Results

Humans utilize the mevalonate pathway to produce IPP. Although human MDD
shares only 31.8 % sequence identity with MDDEF, the key residues in the active site are
highly conserved among MDD proteins67. Thus, the selectivity of potent inhibitors
against MDDEF and hMDD has to be tested. In the published paper, the human form of
MDD can be successfully expressed in the E. coli BL21 (DE3) system using IPTG as an
inducer69. Although we purchased the same plasmid-DNA and used the same expression
protocol, we could not be able to obtain functional human MDD proteins and there was
only a small amount of partially active proteins in the soluble part (data not shown). We
had changed IPTG concentrations, incubation temperature, and different E. coli strains
(RIL and AI) for protein induction; however, it was not compatible with the protein
quality described in the original paper69. A large quantity of proteins was presented in the
inclusion body, and this indicated a fast protein induction. To overcome this problem, we
used the “auto-induction” strategy. From that, we can produce functional human MDD
protein in E. coli BL21 (DE3) and Ni-NTA chromatography to purify human MDD to
homogeneity.
We would be able to obtain the human MDD proteins eluted from the Ni-NTA
column at an imidazole concentration of about 150 mM (Fig. 7.1a, b) and its relative
enzyme activity compared to the wild type MDDEF was determined to be about 26.5%
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(Fig. 7.1c). From the previously published paper, Vmax of human MDD was determined to
be 6.1 ± 0.5 mol/min/mg, KmMVAPP was 28.9 ± 3.3 M, and KmMgATP was 690 ± 70 M69.
Based on these kinetic parameters given in that paper, we could calculate enzymatic
activity of human MDD, and it is about 25% relative to MDDEF under the condition used
in this study. This suggests that we could produce functional human MDD proteins using
auto-induction, and these proteins can be used as a negative control for selecting specific
inhibitors against MDDEF.

a

b

c

Figure 7.1 The purification profile, SDS-PAGE analysis and the relative enzymatic
activity comparison. (a) hMDD proteins were eluted with an increasing imidazole
concentration described above. (b) Samples from the purification steps were analyzed by
SDS-PAGE. (c) The relative enzymatic activity of hMDD was compared with MDDEF
under the condition containing 300 M MVAPP and 1 mM ATP.
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Previously we established the PK/LDH coupling system for monitoring the
enzyme activity of MDDEF, and we have modified the experimental parameters for the
MDDEF HTS screening. High-throughput screening was performed to identify
compounds with potential inhibitory activity against MDDEF. The LOPAC compound
library (1280 compounds) was tested and screening was done in Bindley Biosciences
Center. Z factor was calculated before analyzing inhibitory activity of each compound in
LOPAC. The Z factor of the screening test was calculated using Equation 7.1, where the
symbol “” represents the mean of either positive or negative controls; the symbol
“
negative represent positive controls (with MDDEF addition) and negative controls
(without MDDEF addition).

Z factor=1-

(3σpositive+ 3σnegative)
,
|μpositive - μnegative|
Equation 7.1

A Z-score of 0.7 (greater than 0.5) in our preliminary HTS test indicated an
acceptable assay quality. Using 1 sigma of the mean of negative controls as a selection
criterion, 14 hits with potential inhibitory activity against MDDEF were identified after
HTS and are summarized in Table 7.1.

127
Table 7.1 Hits from HTS.
1

(±)-AMT hydrochloride

2

Gabaculine hydrochloride

3

4-DAMP methiodide

4

(±)-2-Amino-7-phosphonoheptanoic acid

5

Reactive Blue 2

6

5-Aminovaleric acid hydrochloride

7

(±)-Nipecotic acid

8

Mecamylamine hydrochloride

9

Azelaic acid

10

Benzamil hydrochloride

11

PPNDS tetrasodium

12

S-(-)-Carbidopa

13

5-Fluoroindole-2-carboxylic acid

14

GYKI 52466 hydrochloride

After HTS, we then determined the IC50 value for each compound in the
follow-up experiments. The follow-up experiments were conducted at varied
concentrations of each compound from HTS. Each enzymatic reaction was monitored and
the percent inhibition of the enzyme under different conditions was calculated using
Equation 7.2, where “experiment” stands for measured enzymatic activity with the
addition of varied concentrations of a given compound; “background” is readout from a
control without enzyme and inhibitor addition; “Positive control” means measured
enzymatic activity without compound addition.
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Percent inhibition = (1 −

(𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
(𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)

) ∗ 100%
Equation 7.2

The value of percent inhibition of each data point in each compound test was
plotted as a function of inhibitor concentrations. The inhibitory data were represented by
the Michaelis–Menten kinetics model (GraphPad Prism 6) for obtaining the IC50 value in
each case. Fourteen compounds were examined in the follow-up experiments, and two
compounds, 4-DAMP methiodide and Benzamil hydrochloride were identified from the
follow-up experiments. The compound structures and the data fitting results are shown in
Figure 7.2. Both of them have IC50 values of 5 to 10 M. Although the follow-up
experiments indicated these two compounds exhibited promising inhibition activity
against MDDEF, the results cannot be reproduced when we purchased these two
compounds and tested them manually with the in vitro assay (data no shown). In the
discussion session, we will discuss about possible reasons for the false positive results
from HTS and the follow-up experiments, and strategies for improving the data quality.
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Figure 7.2 The molecular structures and the IC50 determination of hits from the
follow-up experiments. (a) The structure of 4-DAMP methiodine. (b) The results of
percent inhibition of MDDEF enzymatic activity at varied concentrations 4-DAMP
methiodine is plotted, and IC50 is indicated. (c) The structure of benzamil hydrochloride.
(d) The results of percent inhibition of MDDEF enzymatic activity at varied
concentrations benzamil hydrochloride are plotted and IC50 is indicated.
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7.5

Discussion

In the design for the high-throughput screening and the follow-up experiments,
we chose a 1536-well plate for loading our samples and use the dispenser to pipette 4 l
of MSA and 1 l of MSB into each well. We found many of the experimental results
showed “unstable” signals, meaning the absorbance readout went up and down during the
enzymatic reaction, and those were not observed in the reactions performed in a 96- or
384-well plate. We thought shorter light path length in a 1536-well plate and sample
homogeneity could be issues. In the future, we might increase the volume of MSB and
adjust the concentrations of components in both MSA and MSB. We think that the
increase in the volume of MSB solution could reduce the effects of pipetting errors from
the dispenser. And a larger volume of MSA-MSB mixture will also increase the path
length, and thus increase the signals according to the Beer-Lambert Law.
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CHAPTER 8. STRUCTURE DETERMINATION OF ISOPENTENYL
DIPHOSPHATE ISOMERASE

8.1

Chapter Summary

In this chapter, we will be focusing on another key enzyme, the type II
isopentenyl diphosphate isomerase from Enterococcus faecalis (IDI-2EF), in the
isoprenoid pathway. This enzyme is downstream of the MDD enzymes and functions to
catalyze the interconversion between IPP and DMAPP, which is another key building
block for polyisoprenoid biosynthesis66,103. In our study, we aim to characterize structural
features and differences between the unbound and FMN-bound forms of IDI-2EF for
designing novel inhibitors which target either conformation for ceasing the enzymatic
activity. The human isopentenyl diphosphate isomerase belongs to the type I IDI (IDI-1),
which is different from IDI-2 family of proteins in sequence and structure104,105, so
ideally we could identify compounds that can specifically bind to the active site pocket.
We have obtained the first crystal structure of unbound IDI-2 from Enterococcus faecalis,
and this structure will confer a structural platform for structure-based drug development
in the future.
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8.2

Introduction

Isopentenyl diphosphate isomerases (IDIs) are ubiquitous enzymes in organisms 66.
The function of these enzymes is to interconvert IPP and DMAPP and maintain the
balance between these two molecules in the cells66. It is known that IPP and DMAPP are
compounds for biosynthesis of polyisoprenoids in living organisms, and two distinct
pathways, the mevalonate (MVA) pathway and the methylerythritol phosphate (MEP)
pathway (Fig. 8.1), are involved in producing IPP and DMAPP. For some organisms
containing the MEP pathway, such as E. coli106, both IPP and DMAPP can be produced
by the end of the pathway, and the isomerases function to balance the concentrations
between IPP and DMAPP; some of organisms, such as Entorococci, Staphyllococci and
Streptococci, contain only the mevalonate pathway107. Thus, the isomerases are
considered essential for the organisms to growth because DMAPP can only be produced
from IPP, the end product of the mevalonate pathway.

133

Figure 8.1 The methylerythritol phosphate (MEP) pathway and the mevalonate
(MVA) pathway. Pyruvate and lyceraldhyde 3-phosphate are compounds for IPP and
DMAPP synthesis in the MEP pathway. In the MVA pathway, three molecules of acetylCoA are condensed to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) followed by 4 steps
of reactions to produce IPP. Isopentenyl diphosphate isomerases (IDI) catalyze
IPP/DMAPP interconversion. The arrow heads represent more steps involved in both the
MEP pathway and the MVA pathway.
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Two types of IDI proteins, IDI-1 and IDI-2, have been characterized structurally
and functionally in the literature103,104,108. Although they catalyze the same reaction, they
are distinct in structure and sequence similarity and the mechanisms differ from each
other. In IDI-1, two conserved residues, cysteine and glutamate, are served as general
acid/base catalysts in the active site; in IDI-2, a reduced FMN molecule is proposed to
play a similar role for IPP/DMAPP isomerization (Fig. 8.2)103. Humans and enterococci
utilize the mevalonate pathway to produce IPP and thus need IDI enzymes to produce
DMAPP. Interestingly, the human genome encodes IDI-1, whereas the enterococci
genome encodes IDI-2. Since IDI-1 does not share protein sequence and structure
homology with IDI-2, IDI-2 becomes a potential therapeutic target for the treatment of
clinical enterococcal infections.

Figure 8.2 The proposed mechanisms of IPP/DMAPP isomerization by IDI-1(red)
and IDI-2 (blue)103. The conserved glutamate and cysteine residues (red) in IDI-1 are
general acid/base catalysts for IPP/DMAPP isomerization. In IDI-2, a reduced form of
FMN (blue) is proposed to be involved in general acid/base catalysis for IPP/DMAPP
interconversion.
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8.3

8.3.1

Materials and Methods

Cloning, expression and purification of the recombinant form of IDI-2EF
The IDI-2EF gene was sub-cloned into the expression plasmid pET-30a (pET-30a-

IDI-2EF). The DNA sequence was confirmed and E. coli BL21 (DE3) cell were
transformed with pET-30a-IDI-2EF73. Transformed cells were cultured in LB broth
supplemented with kanamycin (50 mg/ml) at 37 ℃ to an A600nm of 1.0. Expression of
IDI-2EF proteins was induced by the addition of IPTG to a final concentration of 0.1 mM
for another 4 hours at 37 ℃. Cells were harvested and protein purification steps were the
same as described previously for MDDEF. The C-terminal His-tag can be removed from
IDI-2EF by treatment of recombinant tobacco etch virus (TEV) protease the procedure
was basically the same as used in the previous sessions. The protein solution was further
dialyzed in dialysis buffer again before loaded on a Ni2+-NTA column to remove Histagged TEV proteases and residual His-tagged IDI-2EF. The purified IDI-2EF protein
solution was collected from the flow through and concentrated to 5 mg/ml by
ultrafiltration and stored at -20 ℃.

8.3.2

IDI-2EF protein crystallization, cryo-protection and X-ray data collection and
analysis
The apo-IDI-2EF crystal was obtained by mixing 3 l of 5 mg/ml IDI-2EF protein

solution with 1l of reservoir solution (15% PEG 300, 100 mM sodium citrate, pH 5.6,
and 100 mM MES, pH 6). The drop was equilibrated by vapor diffusion at 20 ℃ in a
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sitting-drop plate. IDI-2EF crystals were flash-frozen in liquid nitrogen with the cryoprotectant (30% PEG 300, 100 mM sodium citrate, pH 5.6, and 100 mM MES, pH 6).
The diffraction data of single apo-IDI-2EF crystal were collected both on the
home-source X-ray radiation at Purdue and the synchrotron at Advance Photon Source
(APS) at Argonne National Laboratory in Chicago (APS). The space group, P4212, was
determined based on the results from Pointless in the CCP4 program75 and
phenix.phaser76. The crystal structure of apo-IDI-2EF was solved by molecular
replacement (phenix.phaser)76 using the crystal structure of IDI-2 from Bacillus subtilis
(IDI-2BS, PDB: 1P0K) as a search model (sequence similarity: 32.6%). Structure
refinement was done in phenix.refine76 and the refinement and structure statistics of apoIDI-2EF was summarized in Table 2.

8.4

Results

Expression of IDI-2EF proteins were successfully induced by IPTG in the E. coli
expression system (BL21). His-tag IDI-2EF proteins were trapped on a Ni2+-NTA column
and then eluted with increasing gradient of imidazole (Fig. 8.3a). The sample from each
step was analysis by SDS-PAGE (Fig. 8.3b). The tag in C-terminus of IDI-2EF was
removed by treatment of TEV protease (Fig. 8.3c). The TEV-treated IDI-2EF protein
solution was then used for crystallization condition screening and condition optimization.
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Figure 8.3 The purification profile and SDS-PAGE analysis. (a) IDI-2EF proteins were
eluted with an increasing imidazole concentration described above. (b) Samples from the
purification steps were analyzed by SDS-PAGE. (c) The C-terminal His tag was removed
from IDI-2EF by treatment of TEV protease under different conditions (#: dialysis buffer
containing 25 mM HEPES, pH 8; * dialysis buffer containing 25 mM Tris-HCl, pH 8). 50
mM of EDTA was used for stripping residual His-tagged proteins off a Ni2+ column.

We have obtained protein crystals of apo-IDI-2EF. The diffraction data were
collected at the home-source radiation and the APS synchrotron, followed by the data
process using HKL2000. The structure resolution was determined as 2.5 Å at the home
source and 2.1 Å at synchrotron. The space group of the apo-IDI-2EF crystal was
determined as P4212. The phases were solved by molecular replacement in
phenix.phase76 using IDI-2 from Bacillus subtilis as a search model. Structure refinement

138
was performed using phenix.refine76 and detailed statistics was summarized in Table 8.1.
The structural model of IDI-2EF was shown in cartoon in Figure 8.4. One macromolecule
in an asymmetric unit was determined by calculating the Mathrew coefficient (Fig. 8.4a)
and there are 8 polypeptide chains in a unit cell (Fig. 8.4b). A tetrameric feature of IDI2EF has known to be conserved among the IDI-2 family of proteins.
For obtaining FMN-bound forms of IDI-2EF, we have done the crystallization
screening for IDI-2EF and the crystal pictures and crystallization conditions are shown in
Figure 8.5. After condition optimization, we were able to obtain bigger yellow crystals
under conditions containing 0.4 to 0.6 M NH4H2PO4 (Fig. 8.6), and the diffraction data
was collect on the home source X-ray equipment. After the structure calculation and
refinement, we could not see a distinct shape of the FMN cofactor in the active site (Data
not shown). This result may result from the phosphate competition, or the oxidized FMN
molecule is disordered in the active site.
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Table 8.1Structural statistics table of apo-IDI-2EF*
Data Collection
Ligands
Crystal conditions
X-ray source and detector
Wavelength (Å )
Space Group
mosaicity
Unit Cell dimensions:
a, b, c (Å )
α=β=γ (°)
Data Processing Statistics
Resolution range (Å )
No. reflection recorded
No. averaged reflections
Redundancy (x-fold)
Rmerge (%)
<I>/<σI>
a
Completeness (%)
Refinement
Resolution Range (Å )
No. Reflections in Working Set
No. Reflections in Test Set
b
Rwork (%)
c

Rfree (%)
Average B-factor (Å ²)
Protein
Solvent
Ligand
No. of Atoms
Protein
Solvent
Ligand
Occupancy of ligand
RMSD from ideal geometry:
Bond Lengths (Å )
Bond Angles (degrees)
Ramachandran Plot
Most Favored (%)
Allowed (%)
Outliers (%)

--Flash-Cooled at 100K
home source_moe
1.54
P4212
0.88
118.5, 118.5, 54.8
90
Overall [Last Shell]
30 - 2.5 [2.59 - 2.50]
148,060
14,065
10.6 [10.5]
12.9 [72.7]
16.7 [2.76]
99.4 [100]
29.6 - 2.5
18,026
908
17.7
20.8
46.53
36.21
--4751
27
---

0.002
0.553
95.1
3.92
0.98

*Structure determined from one crystal. Values in parentheses are for the
highest-resolution shell.
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Figure 8.4 The cartoon model of the apo-IDI-2EF crystal structure. (a) A protein
macromolecule in an asymmetric unit. (b) The total eight polypeptide chains in the unit
cell. The middle part shows a conserved tetrameric architecture among the IDI-2 family
of proteins
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Figure 8.5 IDI-2EF crystallization screening. There are nine crystallization conditions
for the growth of yellow protein crystals after the crystallization screening of IDI-2EF.
Conditions are listed as followings. (Class-I-C1: 0.4 M Ammonium phosphate; Class-IC2: 1 M Ammonium phosphate, 0.1M tri-sodium citrate pH 5.6; JCSG-II-C12: 0.1M
sodium citrate pH 5.5, 50% PEG 200; JCSG-II-E2: 0.1M MES pH 5.0, 10% MPD;
JCSG-II-F10: 0.1M citric acid pH 4.0, 0.8 M ammonium sulfate; JCSG-II-H9: 0.4 M
ammonium dihydrogen phosphate; JCSG-III-C11: 0.1M Tris pH 7.0; 15% Ethanol;
JCSG-III-F2: 0.1M sodium citrate pH 5.5, 35% ethoxyethanol; JCSG-III-F12: 0.1M
sodium citrate pH 5.6, 1M ammonium dihydrogen phosphate).
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Figure 8.6 IDI-2EF crystallization. The protein was dissolved in the buffer containing
Tris (25 mM pH 7.5), NaCl (100 mM) and imidazole (15 mM). The reservoir contains
NH4H2PO4 (0.6M, pH 4) and MES (100mM, pH 5.5). The protein-to-reservoir ratio in the
upper shelf of a hanging drop chamber is 3:1.
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8.5

Discussion

There were some conditions identified from the crystallization screening under
which yellow crystals of IDI-2EF grew within two days (Fig. 8.5). Because the oxidized
FMN cofactor is yellow in solution, it suggests that yellow crystals would have oxidized
FMN binding to the active site of IDI-2EF. In the literature, the FMN molecule can be
reduced by DTT, NADH or sodium thiosulfate (Na2S2O3). In our crystallization buffer,
we added 1 mM DTT to remain the reducing environment, but the crystals were yellow,
suggesting DTT may not be a strong or suitable for preparing a reduced FMN molecule
under those crystallization conditions. In the future, we might perform crystallization
screening again and utilize other reducing agents, and we will also look into the
conditions under which colorless crystals form because those crystals may contain
reduced FMN (colorless).
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APPENDIX

Appendix Table 1 List of structures of MDDEF and IDI-2EF
Folder_directory

lignad in solution

ligand in crystal

/net/stauffacher/chen924/data/MDD/Synch
rotron/20161115_23IDD/D5_MDD_MVP
_ADPBeF3_Mg
/net/stauffacher/chen924/data/MDD/Synch
rotron/20161115_23IDD/D6_MDD_MVP
_ADPBeF3_Mg
/net/stauffacher/chen924/data/MDD/Synch
rotron/22_IDD_20150313/ID22_3_Chun_
MDD_MVP_rS_pH7
/net/stauffacher/chen924/data/MDD/Synch
rotron/22_IDD_20150313/ID22_4_Chun_
MDD_MVP_PCP_1014
/net/stauffacher/chen924/data/MDD/Synch
rotron/22_IDD_20150313/ID22_8_Chun_
MDD_MVP_rS_0721
/net/stauffacher/chen924/data/MDD/Synch
rotron/23IDB_2014_06_20/Co/A10

MVP, ADPBeF3,
Mg2+

MVP, ADPBeF3,
Mg2+

MVP, ADPBeF3,
Mg2+

MVP, ADPBeF3,
Mg2+

MVP, ATPS,
Mg2+

MVP, ADP, SO42, Mg2+

MVP, AMPPCP,
Mg2+

MVP, AMPPCP,
Mg2+

MVP, ATPS,
Mg2+

MVP, ADP, SO42, Mg2+

MVP, AMPPNP,
Co

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, AMPPCP,
rotron/23IDB_2014_06_20/Co/A11
Co

MVP

/net/stauffacher/chen924/data/MDD/Synch Co
rotron/23IDB_2014_06_20/Co/A6
/net/stauffacher/chen924/data/MDD/Synch MVP, Co
rotron/23IDB_2014_06_20/Co/A7

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, ATPS, Co
rotron/23IDB_2014_06_20/Co/A8

MVP, ADP, SO42, Co

/net/stauffacher/chen924/data/MDD/Synch MVP, Mn2+
rotron/23IDB_2014_06_20/Mn/A1

MVP
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/Synch MVP, ATPS, Mn2+ MVP, ADP, SO42-,
rotron/23IDB_2014_06_20/Mn/A2
Mn2+
/net/stauffacher/chen924/data/MDD/Synch MVP, Mn2+
rotron/23IDB_2014_06_20/Mn/A3

MVP

/net/stauffacher/chen924/data/MDD/Synch Mn2+
rotron/23IDB_2014_06_20/Mn/A4
/net/stauffacher/chen924/data/MDD/Synch MVP, Mn2+
rotron/23IDB_2014_06_20/Native/A1

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, AMPPNP,
rotron/23IDB_2014_06_20/Native/A10_x Co

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, AMPPCP,
rotron/23IDB_2014_06_20/Native/A11
Co

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, Mg2+
rotron/23IDB_2014_06_20/Native/A13

MVP

/net/stauffacher/chen924/data/MDD/Synch bad crystal
rotron/23IDB_2014_06_20/Native/A14_x
/net/stauffacher/chen924/data/MDD/Synch MVP, AMPPCP,
rotron/23IDB_2014_06_20/Native/A15
Mg2+

MVP, AMPPCP,
Mg2+ (low
occupancy)

/net/stauffacher/chen924/data/MDD/Synch bad crystal
rotron/23IDB_2014_06_20/Native/A16
/net/stauffacher/chen924/data/MDD/Synch MVP, ATPS, Mn2+
rotron/23IDB_2014_06_20/Native/A2

MVP, ADP, SO42-,
Mn2+

/net/stauffacher/chen924/data/MDD/Synch MVP, Mn2+
rotron/23IDB_2014_06_20/Native/A3

MVP

/net/stauffacher/chen924/data/MDD/Synch Mn2+
rotron/23IDB_2014_06_20/Native/A4
/net/stauffacher/chen924/data/MDD/Synch Co
rotron/23IDB_2014_06_20/Native/A6
/net/stauffacher/chen924/data/MDD/Synch MVP, Co2+
rotron/23IDB_2014_06_20/Native/A7

MVP

/net/stauffacher/chen924/data/MDD/Synch MVP, ATPS Co2+
rotron/23IDB_2014_06_20/Native/A8

MVP, ADP, SO42Co2+
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/Synch bad crystal
rotron/23IDB_2014_06_20/Native/A9_x
/net/stauffacher/chen924/data/MDD/Synch Mg2+
rotron/23IDB_2014_06_20/Native/B1

---

/net/stauffacher/chen924/data/MDD/Synch K187A, MVP,
rotron/23IDB_2014_06_20/Native/B2
ATP, Mg2+

---

/net/stauffacher/chen924/data/MDD/Synch bad crystal
rotron/23IDB_2014_06_20/Native/B4_x
/net/stauffacher/chen924/data/MDD/Synch MVP, ATPS,
rotron/23IDB_2014_06_20/Native/B7
Mg2+

MVP, ADP (low
occupancy)

/net/stauffacher/chen924/data/MDD/Synch K187A, MVP,
rotron/23IDB_2014_06_20/Native/B8
ATPS, Mg2+

MVP

/net/stauffacher/chen924/data/MDD/Synch K187A, MVP,
rotron/23IDB_2014_06_20/Native/B9
ATPS, Mg2+

MVP

/net/stauffacher/chen924/data/MDD/Synch
rotron/MDD_MVAPP_AMPPCP_syn_12
1213/D3
/net/stauffacher/chen924/data/MDD/Synch
rotron/MDD_MVAPP_AMPPCP_syn_12
1213/D4
/net/stauffacher/chen924/data/MDD/Synch
rotron/MDD_MVAPP_ATPrS_syn_12121
3/D5
/net/stauffacher/chen924/data/MDD/Synch
rotron/MDD_MVAPP_ATPrS_syn_12121
3/D6
/net/stauffacher/chen924/data/MDD/Synch
rotron/MDD_MVAPP_syn_121213/D1

MVP, AMPPCP,
Mg2+

---

MVP, AMPPCP,
Mg2+

---

MVP, ATPS,
Mg2+

---

MVP, ATPS,
Mg2+

---

MVP

---

/net/stauffacher/chen924/data/MDD/Synch MVP
rotron/MDD_MVAPP_syn_121213/D2

---

/net/stauffacher/chen924/data/MDD/Synch ATP
rotron/MDDEF_ATP_Syn_110212

ATP
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/Synch Mg2+
rotron/MDDEF_Syn_081613/MDDEF_2_
syn

---

/net/stauffacher/chen924/data/MDD/Synch Mg2+
rotron/MDDEF_Syn_081613/MDDEF_sy
n_good

---

/net/stauffacher/chen924/data/MDD/home
_source/0214_MDD_PEG_MVP_rS

MVP, ATPS,
Mg2+

low occupancy

/net/stauffacher/chen924/data/MDD/home MVP, ATPS,
_source/Curly/0219_MDD_PEG_MVP_rS Mg2+
_2.6

low occupancy

/net/stauffacher/chen924/data/MDD/home
_source/Curly/20151124_MDD_MVP_A
DPSO3

MVP, ADP, SO3,
Mg2+

MVP, ADP (low
occupancy)

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_46_Co_MVP_BeF3
10_ADP_120414

MVP, ADPBeF3,
Co2+

MVP, ADP, SO42, Co2+

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_46_Mg_NO3100_M
VP_ADP_102914

MVP, ADP, NO3-,
Mg2+

MVP, ADP, SO42, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_46_Mg_NO3100_M
VP_ADP_110414

MVP, ADP, NO3-,
Mg2+

MVP, ADP, SO42, Mg2+

/net/stauffacher/chen924/data/MDD/home MVP, ADP, NO3-,
_source/Curly/MDD_46_NO320_Mg_MV Mg2+
P_ADP_102714

MVP, ADP, SO42, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_46NO320_MVP_M
g_ADP_110314

MVP, ADP, NO3-,
Mg2+

MVP, ADP, SO42, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_56_MVP_Co_rS_4h
r_111814

MVP, ATPS, Co2+ MVP
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_7_MVAPP_curly_1
40118
/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_IPP_ADP_0904_cur
ly
/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_MVAPP_AMPPCP_
curly_1031
/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_MVAPP_ATP_curly

MVAPP

---

IPP, ADP, Mg2+

---

MVP, AMPPCP,
Mg2+

---

MVP, ATP, Mg2+

---

/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_MVAPP_curly_102
8
/net/stauffacher/chen924/data/MDD/home
_source/Curly/MDD_MVP_AMPPCP_2_
1101_curly
/net/stauffacher/chen924/data/MDD/home
_source/MDD_PEG3350_MVAPP

MVAPP

---

MVP, AMPPCP,
Mg2+

---

MVAPP

MVAPP

/net/stauffacher/chen924/data/MDD/home
_source/MDD_PEG3350_MVAPP_2

MVAPP

MVAPP

/net/stauffacher/chen924/data/MDD/home
_source/MDD_PEG_MVP_PCP

MVAPP,
AMPPCP, Mg2+

MVAPP,
AMPPCP, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/MDD_Tris7_PEG335024

---

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/1_MDD_PEG_0521

---

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20140413_MDD_PEG_MV
P_Co
/net/stauffacher/chen924/data/MDD/home
_source/moe/20140721_MDD_PEG_MV
P_rS
/net/stauffacher/chen924/data/MDD/home
_source/moe/20140722_MDD_PEG_MV
P_rS_Mn

MVAPP, Co2+

MVAPP

MVAPP, ATPS,
Mg2+

MVAPP, ADP,
SO42-, Mg2+

MVAPP, ATPS,
Mn2+

MVAPP, ADP,
SO42-, Mn2+
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/home
_source/moe/20150331_MDD_PEG_com
pound_194

compound 194
from Nic

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20150401_MDD_PEG_Resv
eratrol

Resveratrol

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20151113_MDD_PEG_MV
P_ATP_BeSO4

MVAPP, ATP, Be,
SO42-

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20151216_MDD_compound
_4

compound 4 from
HTS

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20151217_MDD_compound
_11

compound 11 from
HTS

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/20160409_MDD_MVP_AD
PBeF3_Mg

MVAPP,
ADPBeF3, Mg2+

MVAPP,
ADPBeF3, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/K187A_PEG_MVP_ATP_0
521

MVAPP, ATP

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_MVAPP_0904_moe

MVAPP

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_MVAPP_AMPPCP_
moe

MVAPP,
AMPPCP, Mg2+

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_4656_MVP_rS_
0923

MVAPP, ATPS,
Mg2+

MVAPP, ADP,
SO42-, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_46to7_MVP_rS
_0922

MVAPP, ATPS,
Mg2+

MVAPP, ADP,
SO42-, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_56_MVP_rS_M
g_90m_111814

MVAPP, ATPS,
Mg2+

MVAPP
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_ADP_14
0912

MVAPP, ADP,
Mg2+

MVAPP, ADP,
SO42-, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_ADPBeF
310_Mn_121214

MVAPP,
ADPBeF3, Mn2+

MVAPP, ADP,
SO42-, Mn2+

/net/stauffacher/chen924/data/MDD/home MVAPP, ADP,
_source/moe/MDD_PEG_MVP_ADPNO3 NO3-, Mg2+
_1002

MVAPP, ADP,
SO42-, Mg2+

/net/stauffacher/chen924/data/MDD/home MVAPP, ADP,
_source/moe/MDD_PEG_MVP_ADPNO3 NO3-, Co2+
_Co_1005

MVAPP, ADP
SO42-, Co2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_AlF3_5m
M_ADP_111314

MVAPP, ADP

MVAPP,
ADPAlF3, Mg2+

/net/stauffacher/chen924/data/MDD/home MVAPP,
_source/moe/MDD_PEG_MVP_AMPPCP AMPPCP, Mg2+
_1014

MVAPP,
AMPPCP, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_ATP_Zn
_1006

MVAPP, ATP, Zn

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_BeF35m
M_ADP_111414

MVAPP,
ADPBeF3, Mg2+

MVAPP,
ADPBeF3, Mg2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_BeF3_A
DP_Co_112414

MVAPP,
ADPBeF3, Co2+

MVAPP, ADP,
SO42-, Co2+

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_MVP_rS_Co_0
314

MVAPP, ATPS,
Co2+

MVAPP, ADP,
SO42-, Co2+

/net/stauffacher/chen924/data/MDD/home MVAPP, ADP,
_source/moe/MDD_PEG_NO3100_MVP_ NO3-, Mg2+
ADP_1016

MVAPP, ADP,
SO42-, Mg2+
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_PEG_NO320_MVP_
ADP_1015
/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_Tris7_2_moe_140121

MVAPP, ADP,
NO3-, Mg2+

MVAPP, ADP,
SO42-, Mg2+

---

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDD_Tris_moe_140116

---

---

/net/stauffacher/chen924/data/MDD/home
_source/moe/MDDEF_moe_080713

---

---

/net/stauffacher/chen924/data/IDI2/Structu
re/Synchrotron/20161115_23IDD/D2

---

---

/net/stauffacher/chen924/data/IDI2/Structu
re/Synchrotron/20161115_23IDD/D3

---

---

/net/stauffacher/chen924/data/IDI2/Structu
re/Synchrotron/224273_Apo_T01_D0795
65_P02
/net/stauffacher/chen924/data/IDI2/Structu
re/Synchrotron/224277_FMN_IPP_T01_D
079560_P06
/net/stauffacher/chen924/data/IDI2/Structu
re/Synchrotron/224280_FMN_IPP_Mg_T
01_D079577_P09
/net/stauffacher/chen924/data/IDI2/Structu
re/Home_source/Curly

---

---

FMN, IPP

---

FMN, IPP, Mg2+

---

---

---

/net/stauffacher/chen924/data/IDI2/Structu --re/Home_source/moe/20150624_IDI2_apo

---

/net/stauffacher/chen924/data/IDI2/Structu --re/Home_source/moe/20150707_IDI2_PE
G300_apo
/net/stauffacher/chen924/data/IDI2/Structu FMN
re/Home_source/moe/20150708_IDI2_PE
G300_FMN
/net/stauffacher/chen924/data/IDI2/Structu FMN, IPP
re/Home_source/moe/20150709_IDI2_FM
N_IPP

---

---

---
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued
/net/stauffacher/chen924/data/IDI2/Structu
re/Home_source/moe/20160823_IDI2_So
aking_PEG3350

FMN

---

/net/stauffacher/chen924/data/IDI2/Structu FMN
re/Home_source/moe/20160825_IDI2_FM
N_soaking_PEG3350_big

---

*The diffraction data sets of MDDEF and IDI-2EF in Kandinsky; structures obtained from
the data sets shadowed are presented in this dissertation.
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